



(51) International Patent Classification:

C07K 14/195 (2006.01) C12N 9/38 (2006.01)

(21) International Application Number:

PCT/EP2018/059283

(22) International Filing Date:

11 April 2018 (11.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17166021.0 11 April 2017 (11.04.2017) EP
17188670.8 31 August 2017 (31.08.2017) EP

(71) Applicant: **CHR. HANSEN A/S** [DK/DK]; Boege Alle 10-12, 2970 Hoersholm (DK).

(72) Inventors: **RAJ, Hans**; Bakkehave 8, 1 tv, 2970 Hoersholm (DK). **SMITH, Pernille**; Hoejstrupvej 54, 2700 Broenshoej (DK). **ECKHARDT, Thomas**; Fyrrebakken 11, 3460 Birkerød (DK). **VOJINOVIC, Vojislav**; Noerrevej 8, 3230 Graested (DK). **SCHÖLLER, Charlotte Elisabeth Grüner**; Virumvej 28A, 2830 Virum (DK). **VAN DEN BRINK, Johannes Maarten**; Skelhoejen 1, 2730 Herlev (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: LACTASE ENZYMES WITH IMPROVED PROPERTIES

(57) Abstract: The present invention relates to new improved peptide or dimeric peptides exhibiting beta-galactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions optionally at elevated temperatures.



LACTASE ENZYMES WITH IMPROVED PROPERTIES

FIELD OF THE INVENTION

The present invention relates to new improved peptide or dimeric peptides exhibiting beta-galactosidase enzyme activity as well as improved methods for reducing the lactose content
5 in compositions, such as dairy products.

BACKGROUND OF THE INVENTION

In order to grow on milk, lactose hydrolysis is a good way for lactic acid bacteria to obtain glucose and galactose as carbon source. Lactase (beta-galactosidase; EC 3.2.1.23) is the
10 enzyme that performs the hydrolysis step of the milk sugar lactose into monosaccharides. The commercial use of lactase is to break down lactose in dairy products. Lactose intolerant people have difficulties to digest dairy products with high lactose levels. It is estimated that about 70% of the world's population has a limited ability to digest lactose. Accordingly, there is a growing demand for dairy food products that contain no or only low levels of lactose.

15 Lactases have been isolated from a large variety of organisms, including microorganisms like *Kluyveromyces* and *Bacillus*. *Kluyveromyces*, especially *K. fragilis* and *K. lactis*, and other fungi such as those of the genera *Candida*, *Torula* and *Torulopsis*, are a common source of fungal lactases, whereas *B. coagulans* and *B. circulans* are well known sources for bacterial lactases. Several commercial lactase preparations derived from these organisms are available
20 such as Lactozym® (available from Novozymes, Denmark), HA-Lactase (available from Chr. Hansen, Denmark) and Maxilact® (available from DSM, the Netherlands), all from *K. lactis*. All these lactases are so-called neutral lactases having a pH optimum between pH 6 and pH 8, as well as a temperature optimum around 37°C. When such lactases are used in the production of, e.g. low-lactose yoghurt, the enzyme treatment will either have to be done in
25 a separate step before fermentation or rather high enzyme dosages have to be used because their activity will drop as the pH decreases during fermentation.

A typical process for production of pasteurized milk with reduced lactose comprises addition of the lactase enzyme to the milk followed by prolonged incubation (10-48 h, often 24 h) at temperatures around 6°C. Because the Ha-Lactase and NOLA® Fit activity is in the range of
30 45-70 µmol per min per mg of enzyme of enzyme, enzyme doses in the range of 55-70 mg/L and 45-60mg/L respectively for pasteurized milk are required to achieve the desired residual

lactose level. The Ha-Lactase and NOLA® Fit enzymes have temperature optimum around 37°C. Longer incubation of milk at 37°C can result in microbial growth.

Also, these lactases are not suitable for hydrolysis of lactose in milk performed at high temperature, which would in some cases be beneficial in order to keep the microbial count low and thus ensure high milk quality. Furthermore, the known lactases would not be suitable for use in a desired process for the production of ultra-heat treated (UHT) milk, wherein enzymes were added prior to the UHT treatment.

WO92/13068 relates to compositions comprising lactase activity obtained from sonication of microbial cells of bacteria or yeast. WO2010092057 and WO0104276 relate to cold-active beta-galactosidases. WO07110619 relates to beta-galactosidase with high transgalactosylating activity, whereas WO2009071539 relates to beta-galactosidase with lower transgalactosylating activity.

OBJECT OF THE INVENTION

It is an object of embodiments of the invention to provide beta-galactosidases with properties that enable the production of improved lactose-free or low-lactose products.

It is a further object of embodiments of the invention to provide beta-galactosidases with properties that enable the improved, such as easier, faster, more reliable or less expensive production methods for the lowering of lactose in a product, such as lactose-free or low-lactose products.

SUMMARY OF THE INVENTION

The present inventor(s) have identified beta-galactosidases with properties not previously described that enable the production of improved lactose-free or low-lactose products as well as enabling improved production methods for such lactose-free or low-lactose products. In particular these beta-galactosidases have been shown to be very stable with relatively high activity at a very broad range of both temperatures as well as pH values. They are also useable at specific temperatures, such as at high temperatures and pH values not normally seen with these enzymes. First of all, this enables to the use of beta-galactosidases at specific pH values and temperatures that were not known to be possible. It also enables the use of the same specific enzyme in several different applications, which is highly requested in the industry.

In a first aspect the present invention provides peptides exhibiting an increased beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35, wherein:

- (a) the beta-galactosidase activity is determined by incubating 13 µl of a solution comprising a known amount of a purified lactase enzyme and 37 µl of a solution comprising 140 mM lactose at pH 6.7 and 37°C for 10 min, terminating the lactase reaction by heat, determining the amount of glucose formed by incubating the reaction product at 30°C for 40 min with 80 µL of a solution comprising glucose oxidase (0.6 g/L) 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt) (1.0 g/L, ABTS) and horseradish peroxidase (0.02 g/L) and determining the absorbance at 610 nm using a FLUOphotometer;
- (b) the increase in beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35 is at least 20%.

The enzymes of the present invention are thus characterized by an increase in beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35 which is at least 20%, but may be higher and even significantly higher. Accordingly the present invention provides peptides exhibiting a beta-galactosidase enzyme activity which is increased in comparison to the activity of the peptide of SEQ ID NO:35 by at least 40%, including at least 50% or at least 80%.

According to a preferred embodiment, the above peptides are characterized as having an amino acid sequence selected from SEQ ID NO: 22, 33, 14, 13, 19, 7, 9, 11, 26 and 27, 30 and 1 or having a sequence with an amino acid sequence identity of more than 85% to any of these sequences. As will be shown in the examples of the present application, these peptides were observed to have particularly advantageous beta-galactosidase enzyme activity and according to a preferred embodiment the invention thus provides peptides are characterized as having an amino acid sequence selected from SEQ ID NO: 22, 33, 14, 13, 19, 7, 9, 11, 26 and 27, 30 and 1 or having a sequence with an amino acid sequence identity of more than 85% to any of these sequences and exhibit a beta-galactosidase enzyme activity which is increased in comparison to the activity of the peptide of SEQ ID NO:35 by at least 50%.

In a further embodiment the invention relates peptides exhibiting beta-galactosidase enzyme activity, which have an amino acid sequence represented by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.

In a still further aspect the present invention relates to a dimeric peptide exhibiting beta-galactosidase enzyme activity, which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3; 5 and 6; 20 and 21; 23 and 24; 26 and 27; or 28 and 29, or enzymatically active fragments thereof, or an amino acid sequence of
5 any one thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.

The present invention relates to nucleotide sequences which encode the above peptide or dimeric peptides exhibiting beta-galactosidase enzyme activity according to the invention.

In a further aspect the present invention relates to a host cell comprising a nucleotide
10 sequence which encodes a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity according to the invention.

In one aspect the lactases of the present invention are characterized by a high specific activity. The enzymes were observed to produce 100-300 μmol of glucose formed/min/mg of enzyme of enzyme. The novel lactases thus have a significantly higher activity than the prior
15 art enzymes.

In a further aspect the present invention relates to a method for producing a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity according to the invention, which method comprises the expression of a vector containing a nucleotide sequence according to the invention in a suitable host cell; and purifying said peptide or dimeric
20 peptide from the expression products of said host cell.

In a further aspect the present invention relates to a method for reducing the lactose content in a composition containing lactose, such as in a dairy products, comprising the step of contacting said composition with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33; or which dimeric peptide consist of two peptides having an amino acid sequence represented
25 by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences; or a host cell expressing any one of said peptides, at a pH ranging from 3-10 and at a temperature ranging from 0°C-140°C.

In a further aspect the present invention relates to the use of a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26
30

and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences; or a host cell expressing any one of said peptides for producing a dairy product with a reduced lactose content.

In some embodiments this composition containing lactose or this dairy product is selected from the group consisting of lactose-free milk, low-lactose milk, yoghurt, including unpasteurized as well as pre and post-pasteurized yoghurt, cheese, fermented milk products, dietary supplement and probiotic dietary products. In some other embodiments this host cell is any one selected from a bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*. In some other embodiments the lactose concentration is reduced to less than about 1%, such as to less than about 0.1% or lower, such as to less than about 0.01%.

In a further aspect the present invention relates to a method for producing a dairy product the method comprising the steps of:

a) providing a milk-based substrate comprising lactose;

b) adding a peptide or dimeric peptide exhibiting beta-galactosidase activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33; or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences to said milk-based substrate comprising lactose; and

c) treating said milk-based substrate with said peptide or dimeric peptide exhibiting beta-galactosidase activity.

In one aspect the present invention provides methods for producing a dairy product as described above, wherein:

- (a) the peptide exhibiting beta-galactosidase activity has an amino acid sequence represented by SEQ ID NO: 22, 33, 14, 7, 26 and 27, 30 and 1 or has an amino acid sequence identity of more than 85% to any of these sequences; and
- (b) peptide exhibits an increased beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35, wherein:

- (i) the beta-galactosidase activity is determined by incubating 13 μ l of a solution comprising known amount of a purified lactase enzyme and 37 μ l of a solution comprising 140 mM lactose at pH 6.7 and 37°C for 10 min, terminating the lactase reaction by heat, determining the amount of glucose formed by incubating the reaction product at 30°C for 40 min with 80 μ L of a solution comprising glucose oxidase (0.6 g/L) 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt) (1.0 g/L, ABTS) and horseradish peroxidase (0.02 g/L) and determining the absorbance at 610 nm using a fluophotometer;
- (ii) the increase in beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35 is at least 20%; and
- (c) the step of contacting the composition containing lactose with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity is carried out at a temperature between 50°C and 140°C.

These methods of the present invention may reduce the concentration of lactose in the composition containing lactose or in the milk based substrate to less than 0.2%, preferably less than 0.1%.

In one aspect the methods are designed to reduce the lactose concentration rapidly. According to a preferred embodiment, the present invention thus provides methods as described above, wherein a concentration of less than 0.2% lactose in the composition containing lactose or in the milk based substrate is obtained between 3 and 30 minutes, preferably between 4 and 20 minutes, most preferably between 4 and 10 minutes, after adding the peptide exhibiting beta-galactosidase activity.

In a similar aspect, the present invention provides methods using low concentrations of lactase which are economically advantageous. According to this aspect the methods of the present invention as described above thus add a peptide exhibiting beta-galactosidase activity to the composition containing lactose so that a mixture comprising a concentration of 0.001 to 0.2 mg/ml of the peptide is obtained, preferably a concentration of 0.002 to 0.04 mg/ml of the peptide.

In a further embodiment the above methods provide a rapid decrease in lactose concentration at high temperatures followed by a further decrease at low temperatures. According to this embodiment, methods are provided, wherein the step of contacting the composition containing lactose with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity is carried out at a temperature between 50°C and 140°C for a time period between 4 and 20 minutes and wherein the milk based product is subsequently cooled and

stored until further use at a temperature between 1°C and room temperature, preferably between 1°C and 6°C.

In a further aspect the present invention relates to a dairy product prepared by a method according to the invention. Accordingly, the invention provides a dairy product comprising a peptide exhibiting beta-galactosidase activity having an amino acid sequence represented by
5 SEQ ID NO: 22, 33, 14, 7, 26 and 27, 30 and 1 or an amino acid sequence identity of more than 85% to any of these sequences.

In a further aspect the present invention relates to a food product, such as a dairy product comprising the peptide exhibiting beta-galactosidase activity having an amino acid sequence
10 represented by SEQ ID NO: 22, 33, 14, 7, 26 and 27, 30 and 1 or an amino acid sequence identity of more than 85% to any of these sequences.

More generally, the present invention relates to a food product, such as a dairy product comprising the peptide exhibiting beta-galactosidase activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two
15 peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences.

In a further aspect the present invention relates to a food product, such as a dairy product comprising a host cell expressing a peptide or dimeric peptide exhibiting beta-galactosidase
20 enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences. In some specific embodiments such a food product is selected from beverages, infant foods, cereals, bread,
25 biscuits, confectionary, cakes, food supplements, dietary supplements, probiotic comestible products, prebiotic comestible products, animal feeds, poultry feeds and medicaments, or a dairy product selected from the group consisting of lactose-free milk, low-lactose milk, dried milk powder, baby milks, yoghurt, ice cream, cheese, fermented milk products, dietary supplement and probiotic dietary products.

LEGENDS TO THE FIGURES

Figure 1. The specific activity of the purified enzymes determined at pH 6.7 at 37°C with lactose as substrate, described SUAL-1, discussed in example 6. The measured standard deviation at the given condition was less than 6%.

5 **Figure 2.** The specific activity of the purified enzymes determined at pH 6.7 at 37°C in presence of galactose, described as SUAG, discussed in example 7. The measured standard deviation at the given condition was less than 15%.

Figure 3. The specific activity of the purified enzymes determined at pH 6.7 at 4°C with lactose as substrate, described as SUAL-2, discussed in example 8. The measured standard
10 deviation at the given condition was less than 5%.

Figure 4. The specific activity of the purified enzymes determined at pH 6.7 at 43°C with lactose as substrate, described as SUAL-3, discussed in example 9. The measured standard deviation at the given condition was less than 5%.

Figure 5. The specific activity of the purified enzymes determined at pH 5.5 at 4°C with
15 lactose as substrate, described as SUAL-4, discussed in example 10. The measured standard deviation at the given condition was less than 5%.

Figure 6. The specific activity of the purified enzymes determined at pH 5.5 at 37°C with lactose as substrate, described as SUAL-5, discussed in example 11. The measured standard deviation at the given condition was less than 5%.

20 **Figure 7.** The specific activity of the purified enzymes determined at pH 5.5 at 43°C with lactose as substrate, described as SUAL-6, discussed in example 12. The measured standard deviation at the given condition was less than 5%.

Figure 8. The specific activity of the purified enzymes determined at pH 4.5 at 4°C with lactose as substrate, described as SUAL-7, discussed in example 13. The measured standard
25 deviation at the given condition was less than 5%.

Figure 9. The specific activity of the purified enzymes determined at pH 4.5 at 37°C with lactose as substrate, described as SUAL-8, discussed in example 14. The measured standard deviation at the given condition was less than 5%.

Figure 10. The specific activity of the purified enzymes determined at pH 4.5 at 43°C with
30 lactose as substrate, described as SUAL-9, discussed in example 15. The measured standard deviation at the given condition was less than 5%.

Figure 11. The percentage residual lactose in the pasteurized milk, after the treatment with a fixed amount of the enzyme, after 24 hr at 5°C determined using HPLC.

Figure 12. The percentage residual lactose in the UHT milk, after the treatment with a fixed amount of the enzyme, after 24 hr at 25°C determined using HPLC.

5 **Figure 13.** The percentage residual activity of the purified enzymes at elevated temperatures, determined using lactose as substrate. The activity at pH 6.7 at 37°C was considered as 100%.

Figure 14. The percentage residual lactose present in pasteurized milk after incubation with lactase enzymes at different temperatures, at 37°C, 55°C or 60°C. The detection limit of the
10 LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 15. The percentage residual lactose present in pasteurized milk after incubation with lactase enzymes in a concentration of 0.047 mg/ml. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 16. The percentage residual lactose present in pasteurized milk incubated with
15 lactase enzymes for a different reaction time, namely 15 or 30 minutes. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 17. The percentage residual lactose present in pasteurized milk incubated with lactase enzymes at different enzyme doses, namely 0.047 mg/ml or 0.024 mg/ml. The
20 detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 18. The percentage residual lactose present in pasteurized milk incubated with lactase enzymes using a different dose and a different reaction time. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 19. The percentage residual lactose present in filtered milk incubated with lactase
25 enzymes at 55°C. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 20. The percentage residual lactose present in filtered milk incubated with lactase enzymes at 55°C and at different enzyme doses. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

30 **Figure 21.** The percentage residual lactose present in filtered milk incubated with lactase enzymes at 55°C for a different reaction time. The detection limit of the LactoSens® kit used in the assay is either 0.01% to 0.2% or 0.02%-1.0% lactose.

Figure 22. The measured specific activity of purified enzymes determined at pH 6.7 at different temperatures. The specific activity values were defined as μmole of glucose formed per minute per milligram of enzyme under a given condition. The measured standard deviations at the given conditions were between 5-11%.

5 **Figure 23.** The measured specific activity of purified enzymes determined at pH 5.5 at different temperatures. The specific activity values were defined as μmole of glucose formed per minute per milligram of enzyme under a given condition. The measured standard deviations at the given conditions were around 5%.

10 **Figure 24.** The measured specific activity of purified enzymes determined at pH 4.5 at different temperatures. The specific activity values were defined as μmole of glucose formed per minute per milligram of enzyme under a given condition. The measured standard deviations at the given conditions were around 5%.

DETAILED DISCLOSURE OF THE INVENTION

15 The present inventors have found that certain peptides and dimeric peptides exhibiting beta-galactosidase enzyme activity are surprisingly stabile at many different physical conditions giving a relatively high activity outside of the ranges normally seen to be optimal for this class of enzymes.

Accordingly, these by the present inventors identified enzymes have a relatively high activity
20 around 4°C or 5°C and may thus be used for lactose hydrolysis in the production of e.g. fresh milk. Moreover, the enzymes have also a relatively high activity in the range of 10°C- 25°C and the exact same enzymes may thus be used for lactose hydrolysis in UHT milk. This feasibility of the enzymes even at broad ranges of temperatures is highly relevant since milk may be stored at room/ambient temperature which may be different in different parts of the
25 world, also depending on the seasons. For the UHT treatment, the temperature is typically either around 135°C or around 140°C. It is highly wanted that the enzymes may have activity in the range of a temperature up to 140°C so that the enzyme may be added to raw milk before the UHT step. In the current practices the enzyme is added after the UHT step because the enzymes known in the art has a significant decrease in functional activity, such
30 as to a value below measurable activity following the high heat treatment step. Also the milk is stored at room temperature which may vary significantly in different parts of the world.

Also these novel improved peptides exhibiting beta-galactosidase enzyme activity have been found to have activity in the temperature range normally used for pasteurization.

Accordingly, these enzymes may be added to raw milk prior to pasteurization. It is to be understood that the enzymes known in the art has a significant decrease in functional activity, such as to a value below measurable activity following a pasteurization step.

5 A further advantage of these novel improved peptides exhibiting beta-galactosidase enzyme activity is that they have a relatively low degree of galactose inhibition. The lower galactose inhibition of these novel enzymes is highly relevant for applications wherein very low lactose concentrations are desired.

10 In terms of applicability for fermented products it is highly advantageous that the enzymes as described herein have a high beta-galactosidase enzymatic activity at a relatively broad temperature range of between 4°C -43°C, such as around 37°C, where fermentation would normally be optimal, but also that this activity of the beta-galactosidase enzyme is present at low pH, such as down to 4.5, or down to 4.0, or down to 3.5, or even down to pH 3.

15 In summary, it has been found by the present inventors that some peptides exhibiting beta-galactosidase enzyme activity is active over wide range of temperature, active over wide range of pH, has a general high hydrolytic activity without side activities, that these peptides have no or little galactose inhibition, such as less than 60%, and that they are stable over long-term storage.

20 The beta-galactosidase activity may be determined by measuring the amount of released glucose after incubation with lactose at set conditions. Released glucose can be detected by a coloring reaction.

Definitions

The term "milk", as used herein and in the context of the present invention, is to be understood as the lacteal secretion obtained by milking any mammal, such as cow, sheep, goats, buffalo or camel.

25 The term "composition containing lactose" as used herein refers to any composition, such as any liquid that contain lactose in significant measurable degree, such as a lactose content higher than 0.002% (0.002 g/100ml). Encompassed within this term are milk and milk-based substrates.

30 The term "milk-based substrate", in the context of the present invention, may be any raw and/or processed milk material. Useful milk-based substrates include, but are not limited to solutions/suspensions of any milk or milk like products comprising lactose, such as whole or low fat milk, skim milk, buttermilk, low-lactose milk, reconstituted milk powder, condensed

milk, solutions of dried milk, UHT milk, whey, whey permeate, acid whey, cream, fermented milk products, such as yoghurt, cheese, dietary supplement and probiotic dietary products. Typically the term milk-based substrate refers to a raw or processed milk material that is processed further in order to produce a dairy product.

- 5 The term "pasteurization" as used herein refers to the process of reducing or eliminating the presence of live organisms, such as microorganisms in a milk-based substrate. Preferably, pasteurization is attained by maintaining a specified temperature for a specified period of time. The specified temperature is usually attained by heating. The temperature and duration may be selected in order to kill or inactivate certain bacteria, such as harmful bacteria,
10 and/or to inactivate enzymes in the milk. A rapid cooling step may follow.

The term "dairy product" as used herein may be any food product wherein one of the major constituents is milk-based. Usually the major constituent is milk-based and in some embodiments, the major constituent is a milk-based substrate which has been treated with an enzyme having beta-galactosidase activity according to a method of the present invention.

- 15 A dairy product according to the invention may be, e.g., skim milk, low fat milk, whole milk, cream, UHT milk, milk having an extended shelf life, a fermented milk product, cheese, yoghurt, butter, dairy spread, butter milk, acidified milk drink, sour cream, whey based drink, ice cream, condensed milk, dulce de leche or a flavored milk drink.

- 20 A dairy product may additionally comprise non-milk components, e.g. vegetable components such as, e.g., vegetable oil, vegetable protein, and/or vegetable carbohydrates. Dairy products may also comprise further additives such as, e.g., enzymes, flavoring agents, microbial cultures such as probiotic cultures, salts, sweeteners, sugars, acids, fruit, fruit prep, fruit juices, or any other component known in the art as a component of, or additive to, a dairy product.

- 25 The terms "fermented dairy product" or "fermented milk product" as used herein is to be understood as any dairy product wherein any type of fermentation forms part of the production process. Examples of fermented dairy products are products like yoghurt, buttermilk, creme fraiche, quark and fromage frais. A fermented dairy product may be produced by or include steps of any method known in the art.

- 30 The term "fermentation" as used herein refers to the conversion of carbohydrates into alcohols or acids through the action of a microorganism. In some embodiments fermentation according to the present invention comprises the conversion of lactose to lactic acid. In the

context of the present invention, "microorganism" may include any bacterium or fungus being able to ferment the milk substrate.

The term "increased beta-galactosidase enzyme activity" as used herein refers to a relatively higher specific activity of a beta-galactosidase enzymes in comparison to a reference sequence.

The term "peptide exhibiting beta-galactosidase enzyme activity" as used herein refers to any peptide, which has enzymatic activity to catalyze the hydrolysis of the disaccharide lactose into its component monosaccharides glucose and galactose. This peptide may also be referred to as a lactase or simply a beta-galactosidase (EC: 3.2.1.23).

10 In a preferred embodiment the beta-galactosidase activity is determined by incubating 13 μ l of a solution comprising a known amount of a purified lactase enzyme with a solution comprising 140 mM of lactose at pH 6.7 and 37°C for 10 min, terminating the lactase reaction by increasing the temperature to 95 °C for 10 min. The amount of glucose formed was determined by incubating the reaction product at 30°C for 40 min with a 80 μ L solution
15 of glucose oxidase (0.6 g/L), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt) (1.0 g/L ABTS) and horseradish peroxidase (0.02 g/L) and determining the absorbance at 610 nm using a fluophotometer. The absorbance is correlated to the concentration of glucose formed per minute and the maximum value determined (in μ mol of glucose formed/min) is determined as the Unit of Lactase Activity 1 (also designated herein
20 UAL-1). The Specific Activity of Lactase (also herein designated SUAL-1) at pH 6.7 at 37°C is defined as μ mol of glucose formed/min/mg of enzyme and is determined by dividing UAL-1 by the lactase protein concentration in mg. Full details of a preferred alternative of carrying out this assay are illustrated in Example 6.

While characterizing beta-galactosidase activity by reference to values of the unit μ mol of
25 glucose formed/min/mg of enzyme represents the standard approach for the determination of the activity, other units may equally be used to characterize the activity of the lactase enzymes using the above test. Accordingly, some of the examples characterize the lactase enzyme activity by reference to μ M of glucose formed per second per μ M of enzyme.

In alternative embodiments the assay can be carried out using a different temperature or
30 different pH values for the lactase incubation.

The terms "peptide" and "oligopeptide" as used in the context of this present application are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids

coupled by peptidyl linkages. The word "polypeptide" is used herein for chains containing more than ten amino acid residues. All peptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus. "Proteins" as used herein refers to peptide sequences as they are produced by some host
5 organism and may include posttranslational modification, such as added glycans.

The terms "amino acid" or "amino acid sequence," as used herein, refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, "fragment" refer to fragments of a peptide exhibiting beta-galactosidase enzyme activity, which retain some enzymatic activity. Where
10 "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited peptide molecule.

Exemplary peptides of the invention also include fragments of at least about 50,100,150,
15 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800 or more residues in length, or over the full length of an enzyme. Accordingly a "peptide fragment" or "enzymatically active fragment" of the invention are fragments that retain at least some functional enzymatic activity. Typically a peptide fragment of the invention will still contain the functional catalytic domain or other essential active sites of the peptide exhibiting beta-
20 galactosidase enzyme activity. Other domains may be deleted.

Typically, the specific beta-galactosidase enzyme activity will be measured and indicated as μmol of glucose formed/min/mg of enzyme used. This specific value however will vary depending on conditions applied, such as temperature, and pH. Accordingly, values for beta-galactosidase enzyme activity may also be referred to as relative to a reference known
25 enzyme, such as the beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35.

Unless otherwise stated the term "Sequence identity" for amino acids as used herein refers to the sequence identity calculated as $(n_{ref} - n_{dif}) \cdot 100 / n_{ref}$, wherein n_{dif} is the total number of non-identical residues in the two sequences when aligned and wherein n_{ref} is the number of residues in one of the sequences.

30 In some embodiments the sequence identity is determined by conventional methods, e.g., Smith and Waterman, 1981, Adv. Appl. Math. 2:482, by the search for similarity method of Pearson & Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, using the CLUSTAL W algorithm of Thompson et al., 1994, Nucleic Acids Res 22:467380, by computerized implementations of

these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group). The BLAST algorithm (Altschul et al., 1990, Mol. Biol. 215:403-10) for which software may be obtained through the National Center for Biotechnology Information www.ncbi.nlm.nih.gov/) may also be used. When using any of the
5 aforementioned algorithms, the default parameters for "Window" length, gap penalty, etc., are used.

A peptide with a specific amino acid sequence as described herein may vary from a reference peptide sequence by any of amino acid substitutions, additions/insertions, or deletions.

Some embodiments according to the present invention refers to the use of a peptide with an
10 amino acid sequence represented by SEQ ID NO:1-33 or a sequence with at least 80 % sequence identity to any one of said sequences. In some embodiments this sequence identity may be at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, such as a peptide with not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid
15 substitutions, additions or deletions as compared to any one reference amino acid sequence represented by SEQ ID NO:1-33. The invention also features biologically active fragments of the peptides according to the invention. Biologically active fragments of a peptide of the invention include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of peptide of the invention which include fewer amino acids
20 than the full length protein but which exhibit a substantial part of the biological activity of the corresponding full-length peptide. Typically, biologically active fragments comprise a domain or motif with at least one activity of a variant protein of the invention. A biologically active fragment of a peptide of the invention can be a peptide which is, for example, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acids in length.

25 The term "host cell", as used herein, includes any cell type which is susceptible to transformation, transfection, transduction, and the like with a nucleic acid construct or expression vector comprising a polynucleotide encoding the peptides of the present invention. A host cell may be the cell type, where a specific enzyme is derived from or it may be an alternative cell type susceptible to the production of a specific enzyme. The term includes
30 both wild type and attenuated strains.

Suitable host cell may be any bacteria including lactic acid within the order "Lactobacillales" which includes *Lactococcus spp.*, *Streptococcus spp.*, *Lactobacillus spp.*, *Leuconostoc spp.*, *Pseudoleuconostoc spp.*, *Pediococcus spp.*, *Brevibacterium spp.*, *Enterococcus spp.* and *Propionibacterium spp.* Also included are lactic acid producing bacteria belonging to the group

of anaerobic bacteria, bifidobacteria, i.e. *Bifidobacterium spp.*, which are frequently used as food cultures alone or in combination with lactic acid bacteria. Also included within this definition are *Lactococcus lactis*, *Lactococcus lactis subsp. cremoris*, *Leuconostoc mesenteroides subsp. cremoris*, *Pseudoleuconostoc mesenteroides subsp. cremoris*,
5 *Pediococcus pentosaceus*, *Lactococcus lactis subsp. lactis biovar. diacetylactis*, *Lactobacillus casei subsp. casei* and *Lactobacillus paracasei subsp. Paracasei* and thermophilic lactic acid bacterial species include as examples *Streptococcus thermophilus*, *Enterococcus faecium*, *Lactobacillus delbrueckii subsp. lactis*, *Lactobacillus helveticus*, *Lactobacillus delbrueckii subsp. bulgaricus* and *Lactobacillus acidophilus*. Other specific bacteria within this definition
10 includes bacteria of the family Bifidobacteriaceae, such as from the genus *Bifidobacterium*, such as from a strain of *bifidobacterium animalis* or *bifidobacterium longum*, *bifidobacterium adolescentis*, *bifidobacterium bifidum*, *bifidobacterium breve*, *bifidobacterium catenulatum*, *bifidobacterium infantis* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. Lactis*, and *L. helveticus*.

Also included within this definition of host cells include strain of *Agaricus*, e.g. *A. bisporus*; *Ascovaginospora*; *Aspergillus*, e.g. *A. niger*, *A. awamori*, *A. foetidus*, *A. japonicus*, *A. oryzae*; *Candida*; *Chaetomium*; *Chaetotomastia*; *Dictyostelium*, e.g. *D. discoideum*; *Kluveromyces*, e.g. *K. fragilis*, *K. lactis*; *Mucor*, e.g. *M. javanicus*, *M. mucedo*, *M. subtilissimus*; *Neurospora*, e.g. *N. crassa*; *Rhizomucor*, e.g. *R. pusillus*; *Rhizopus*, e.g. *R. arrhizus*, *R. japonicus*, *R.*
20 *stolonifer*; *Sclerotinia*, e.g. *S. libertiana*; *Torula*; *Torulopsis*; *Trichophyton*, e.g. *T. rubrum*; *Whetzelinia*, e.g. *W. sclerotiorum*; *Bacillus*, e.g. *B. coagulans*, *B. circulans*, *B. megaterium*, *B. novalis*, *B. subtilis*, *B. pumilus*, *B. stearothermophilus*, *B. thuringiensis*; *Bifidobacterium*, e.g. *B. longum*, *B. bifidum*, *B. animalis*; *Chryseobacterium*; *Citrobacter*, e.g. *C. freundii*; *Clostridium*, e.g. *C. perfringens*; *Diplodia*, e.g. *D. gossypina*; *Enterobacter*, e.g. *E. aerogenes*,
25 *E. cloacae* *Edwardsiella*, *E. tarda*; *Erwinia*, e.g. *E. herbicola*; *Escherichia*, e.g. *E. coli*; *Klebsiella*, e.g. *K. pneumoniae*; *Miriococcum*; *Myrothesium*; *Mucor*; *Neurospora*, e.g. *N. crassa*; *Proteus*, e.g. *P. vulgaris*; *Providencia*, e.g. *P. stuartii*; *Pycnopus*, e.g. *Pycnopus cinnabarinus*, *Pycnopus sanguineus*; *Ruminococcus*, e.g. *R. torques*; *Salmonella*, e.g. *S. typhimurium*; *Serratia*, e.g. *S. liquefaciens*, *S. marcescens*; *Shigella*, e.g. *S. flexneri*;
30 *Streptomyces*, e.g. *S. antibioticus*, *S. castaneoglobisporus*, *S. violeceoruber*; *Trametes*; *Trichoderma*, e.g. *T. reesei*, *T. viride*; *Yersinia*, e.g. *Y. enterocolitica*.

Specific embodiments of the invention

As described above the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 1, 2, 3, 4, 5,

6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.

- 5 Accordingly, in one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase
- 10 enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 2, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 3, or an amino acid
- 15 sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 4, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
- 20 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 5, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present
- 25 invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 6, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an
- 30 amino acid sequence represented by SEQ ID NO: 7, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 8, or an amino acid sequence thereof
- 35 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,

or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 9, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 5 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 10, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 10 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 11, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 15 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 12, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 20 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 13, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 14, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 30 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 15, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 35 or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 16, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 17, or an amino acid sequence thereof

having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 18, or an amino acid sequence thereof

5 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 19, or an amino acid sequence thereof

10 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 20, or an amino acid sequence thereof

15 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 21, or an amino acid sequence thereof

20 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 22, or an amino acid sequence thereof

25 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 23, or an amino acid sequence thereof

30 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 24, or an amino acid sequence thereof

35 having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an

amino acid sequence represented by SEQ ID NO: 26, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 27, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 28, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 29, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 30, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 31, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 32, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions. In one embodiment the present invention relates to a peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 33, or an amino acid sequence thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 8 described herein at a temperature of about 4°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID

NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μmol of glucose formed/min/mg of enzyme at a temperature of about 4°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/minsec/mg of enzyme μM of enzyme at a temperature of about 4°C and a pH of 6.7, which activity is higher than about 2, such as higher than about 4, such as higher than about 6, such as higher than about 8, such as higher than about 10, such as higher than about 12, such as higher than about 14, such as higher than about 16 μmol μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/minsec/mg of enzyme μM of enzyme under conditions as given in example 10 described herein at a temperature of about 4°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 4°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as

at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 4°C and a pH of 5.5, which activity is higher than about 1, such as higher than about 2, such as higher than about 3, such as higher than about 4, such as higher than about 5, such as higher than about 6, such as higher than about 7, such as higher than about 8 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 13 described herein at a temperature of about 4°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 4°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 4°C and a pH of 4.5, which activity is higher than about 0.5, such as higher than about 1.0, such as higher than about 1.5, such as higher than about 2.0, such as higher than about 2.5, such as higher than about 3.0, such as higher than about 3.5, such as higher than about 4.0 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 9 described herein at a temperature of about 43°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such

as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

- 5 In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%,
10 such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 6.7, which activity is higher than about
15 10, such as higher than about 20, such as higher than about 40, such as higher than about 60, such as higher than about 80, such as higher than about 100, such as higher than about 120, such as higher than about 140, such as higher than about 160 μM of glucose formed/sec/ μM of enzyme. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under
20 conditions as given in example 12 described herein at a temperature of about 43°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about
25 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

- In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme
30 defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according

to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 5.5, which activity is higher than about 5, such as higher than about 10, such as higher than about 15, such as higher than about 20, such as higher than about 25, such as higher than about 30, such as higher than about 35, such as higher than about 40, such as higher than about 45, such as higher than about 50, such as higher than about 55, such as higher than about 60 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 15 described herein at a temperature of about 43°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 43°C and a pH of 4.5, which activity is higher than about 1, such as higher than about 2, such as higher than about 3, such as higher than about 4, such as higher than about 5, such as higher than about 6, such as higher than about 7, such as higher than about 8, such as higher than about 9, such as higher than about 10, such as higher than about 11, such as higher than about 12 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 6 described herein at a temperature of about 37°C and a pH of 6.7, which activity is

exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 37°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%. In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 37°C and a pH of 6.7, which activity is higher than about 10, such as higher than about 20, such as higher than about 30, such as higher than about 40, such as higher than about 50, such as higher than about 60, such as higher than about 70, such as higher than about 80, such as higher than about 90, such as higher than about 100, such as higher than about 110, such as higher than about 120, such as higher than about 130 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in example 11 described herein at a temperature of about 37°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 37°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about

30%, such as at least about 40%, such as at least about 50%, such as at least about 60%,
such as at least about 70%, such as at least about 80%, such as at least about 90%, such as
at least about 100%, such as at least about 200%, such as at least about 300%, such as at
least about 400%, such as at least about 500%. In some embodiments the peptide according
5 to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM
of enzyme at a temperature of about 37°C and a pH of 5.5, which activity is higher than
about 5, such as higher than about 10, such as higher than about 15, such as higher than
about 20, such as higher than about 25, such as higher than about 30, such as higher than
about 35, such as higher than about 40, such as higher than about 45, such as higher than
10 about 50, such as higher than about 55, such as higher than about 60 μM of glucose
formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention has a beta-galactosidase
activity measured as μM of glucose formed/sec/ μM of enzyme under conditions as given in
example 14 described herein at a temperature of about 37°C and a pH of 4.5, which activity
15 is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 or SEQ ID
NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such
as at least about 50%, such as at least about 60%, such as at least about 70%, such as at
least about 80%, such as at least about 90%, such as at least about 100%, such as at least
about 200%, such as at least about 300%, such as at least about 400%, such as at least
20 about 500%.

In some embodiments the peptide according to the invention has a beta-galactosidase
activity measured as μM of glucose formed/sec/ μM of enzyme at a temperature of about 37°C
and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme
defined by SEQ ID NO:34 or SEQ ID NO:35 by at least about 20%, such as at least about
25 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%,
such as at least about 70%, such as at least about 80%, such as at least about 90%, such as
at least about 100%, such as at least about 200%, such as at least about 300%, such as at
least about 400%, such as at least about 500%. In some embodiments the peptide according
to the invention has a beta-galactosidase activity measured as μM of glucose formed/sec/ μM
30 of enzyme at a temperature of about 37°C and a pH of 4.5, which activity is higher than
about 1, such as higher than about 2, such as higher than about 3, such as higher than about
4, such as higher than about 5, such as higher than about 6, such as higher than about 7,
such as higher than about 8, such as higher than about 9, such as higher than about 10, such
as higher than about 11, such as higher than about 12, such as higher than about 13, such

as higher than about 14, such as higher than about 15, such as higher than about 16, such as higher than about 17, such as higher than about 18 μM of glucose formed/sec/ μM of enzyme.

In some embodiments the peptide according to the invention is derived from a bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*.

In some embodiments the peptide according to the invention exhibit a galactose inhibition less than 60%, such as less than 55%, such as less than 50%, such as less than about 45%, such as less than about 40%.

As described above at part of the present invention relates to a method for producing a dairy product the method comprising the steps of

a) providing a milk-based substrate comprising lactose;
b) adding an peptide exhibiting beta-galactosidase activity and having an amino acid sequence represented by SEQ ID NO:1-33 or a sequence with at least 80 % sequence identity to any one of said sequences to said milk-based substrate comprising lactose; and
c) treating said milk-based substrate with said peptide exhibiting beta-galactosidase activity.

In one aspect these methods for producing a dairy product comprise steps of:

a) providing a milk-based substrate comprising lactose;
b) adding a peptide exhibiting beta-galactosidase activity and having an amino acid sequence represented by SEQ ID NO: 22, 33, 14, 7, 26 and 27, 30 and 1 (sequence of G4, G16, G33, G40, G44, G66, G95, G158, G282 and G335) or having an amino acid sequence identity of more than 85% to any of these sequences to said milk-based substrate comprising lactose; and
c) treating said milk-based substrate with said peptide exhibiting beta-galactosidase activity at a temperature between 50°C and 140°C.

The method can be carried out in a manner to reduce the concentration of lactose in the milk based substrate to less than 0.2%, preferably less than 0.1%. In a preferred embodiment of this aspect the method is carried out such that a concentration of less than 0.2% lactose in the milk based substrate is obtained between 3 and 30 minutes, preferably between 4 and 20 minutes, most preferably between 4 and 10 minutes, after adding the peptide exhibiting beta-galactosidase activity.

In one embodiment the method uses a peptide exhibiting beta-galactosidase activity which have an amino acid sequence represented by SEQ ID NO:22, 33, 14 or 7 or an amino acid sequence identity of more than 85% to any of these sequence.

5 The method may make use of low concentrations of the peptide exhibiting beta-galactosidase activity and having an amino acid sequence represented by SEQ ID NO:22, 33, 14 or 7 or an amino acid sequence identity of more than 85% to any of these sequences, such as a concentration of 0.001 to 0.2 mg/ml, preferably of 0.002 to 0.04 mg/ml.

10 It is preferred that the incubation at high temperature be limited to a short period of time. In a particularly preferred embodiment, the present invention provides methods as described above, wherein step c) is carried at a temperature between 50°C and 140°C for a time period between 4 and 20 minutes and the milk based product is subsequently cooled and stored until further use at a temperature between 1°C and room temperature, preferably between 1°C and 6°C.

15 In some embodiments according to the present invention this peptide is derived from any one bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*.

20 In some embodiments according to the present invention step c) takes place at a pH within a range of 3-10, such as within a range of 3-9, such as within a range of 3-8, such as within a range of 3-7, such as within a range of 3-6, such as within a range of 3-5, such as within a range of 3-4, such as within a range of 4-10, such as within a range of 4-9, such as within a range of 4-8, such as within a range of 4-7, such as within a range of 4-6, such as within a range of 4-5, such as within a range of 5-10, such as within a range of 5-9, such as within a range of 5-8, such as within a range of 5-7, such as within a range of 5-6, such as within a range of 6-10, such as within a range of 6-9, such as within a range of 6-8, such as within a range of 6-7.

30 In some embodiments according to the present invention step c) or a part of step c) takes place at a temperature of not more than about 25°C, such as not more than about 20 °C, such as not more than about 18 °C, such as not more than about 16 °C, such as not more than about 14 °C, such as not more than about 12 °C, such as not more than about 10 °C, such as not more than about 8 °C, such as not more than about 7 °C, such as not more than

about 6 °C, such as not more than about 5 °C, such as not more than about 4 °C, such as not more than about 3 °C, such as not more than about 2 °C.

In some embodiments according to the present invention step c) or a part of step c) takes place at a temperature of at least about 25 °C, such as at least about 30 °C, such as at least about 35 °C, such as at least about 40 °C, such as at least about 45 °C, such as at least about 50 °C, such as at least about 55 °C, such as at least about 60 °C, such as at least about 65 °C, such as at least about 70 °C, such as at least about 75 °C, such as at least about 80 °C, such as at least about 85 °C, such as at least about 90 °C, such as at least about 95 °C, such as at least about 100 °C, such as at least about 110 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 135 °C, such as at least about 140 °C.

In some embodiments according to the present invention the dairy product is selected from the group consisting of lactose-free milk, low-lactose milk, yoghurt, cheese, fermented milk products, dietary supplement and probiotic dietary products.

In some embodiments according to the present invention the milk-based substrate is selected from fresh milk or raw milk obtained directly from a step of pasteurization, milk obtained directly after a step of ultra-heat treatment (UHT), or milk obtained directly after a step of fermentation.

In some embodiments according to the present invention the galactose inhibition of the peptide used is less than 60%, such as less than 55%, such as less than 50%, such as less than about 45%, such as less than about 40%.

In some embodiments according to the present invention the dairy product is fermented milk product and said step b) is performed during or prior to fermentation.

In some embodiments according to the present invention the method does not require the addition of further enzyme after fermentation.

In some embodiments according to the present invention the dairy product is fermented milk product and said step b) is performed immediately following fermentation.

In some embodiments according to the present invention the dairy product is fresh milk and said step b) is performed prior to, in conjunction with, or immediately following a step of pasteurization.

In some embodiments according to the present invention the dairy product is ultra-heat treatment (UHT) milk and said step b) is performed prior to, in conjunction with, or immediately following a step of ultra-heat treatment.

In some embodiments according to the present invention step c) is started at a temperature
5 of between 40°C and 100°C, such as at a temperature of between 50°C and 100°C such as
at a temperature of between 60°C and 100°C, such as at a temperature of between 70°C and
100°C, such as at a temperature of between 80°C and 100°C, such as at a temperature of
between 40°C and 90°C, such as at a temperature of between 40°C and 80°C, such as at a
temperature of between 40°C and 70°C, such as at a temperature of between 40°C and
10 60°C, such as at a temperature of between 40°C and 50°C.

In some embodiments according to the present invention the peptide when hydrolyzing the lactose in the milk-based substrate has a ratio of lactase to transgalactosylase activity of more than 1:1.

In some embodiments according to the present invention less than 80% of the lactose has
15 been hydrolyzed when step c) is completed, and wherein more than 90% of the lactose has
been hydrolyzed after one week.

Numbered embodiments:

1. A peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid
20 sequence represented by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or enzymatically active
fragments thereof, or an amino acid sequence of any one thereof having not more than 1, 2,
3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid
substitutions, additions or deletions.

25 2. A dimeric peptide exhibiting beta-galactosidase enzyme activity, which dimeric peptide
consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3,
5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or enzymatically active fragments
thereof, or an amino acid sequence of any one thereof having not more than 1, 2, 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions,
30 additions or deletions.

3. The peptide or dimeric peptide according to embodiments 1 or 2, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under

conditions as given in example 8 described herein at a temperature of about 4°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

4. The peptide or dimeric peptide according to any one of embodiments 1-3, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 10 described herein at a temperature of about 4°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

5. The peptide or dimeric peptide according to any one of embodiments 1-4, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 13 described herein at a temperature of about 4°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

6. The peptide or dimeric peptide according to any one of embodiments 1-5, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 9 described herein at a temperature of about 43°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

7. The peptide or dimeric peptide according to any one of embodiments 1-6, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 12 described herein at a temperature of about 43°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

10 8. The peptide or dimeric peptide according to any one of embodiments 1-7, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 15 described herein at a temperature of about 43°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

20 9. The peptide or dimeric peptide according to any one of embodiments 1-8, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 6 described herein at a temperature of about 37°C and a pH of 6.7, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

30 10. The peptide or dimeric peptide according to any one of embodiments 1-9, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 11 described herein at a temperature of about 37°C and a pH of 5.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

11. The peptide or dimeric peptide according to any one of embodiments 1-10, which has a beta-galactosidase activity measured as μM of glucose formed per second per μM of enzyme under conditions as given in example 14 described herein at a temperature of about 37°C and a pH of 4.5, which activity is exceeding the activity of a beta-galactosidase enzyme defined by SEQ ID NO:34 OR SEQ ID NO:35 by at least about 20%, such as at least about 30%, such as at least about 40%, such as at least about 50%, such as at least about 60%, such as at least about 70%, such as at least about 80%, such as at least about 90%, such as at least about 100%, such as at least about 200%, such as at least about 300%, such as at least about 400%, such as at least about 500%.

12. The peptide or dimeric peptide according to any one of embodiments 1-11, derived from a bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*.

13. The peptide or dimeric peptide according to any one of embodiments 1-12, wherein said peptide or dimeric peptide exhibit a galactose inhibition less than 60%, such as less than 55%, such as less than 50%, such as less than about 45%, such as less than about 40%.

14. A nucleotide sequence which encodes a peptide or dimeric peptide as defined in any one of embodiments 1-13.

15. A host cell comprising a nucleotide sequence as defined in embodiment 14.

16. A method for producing a peptide or dimeric peptide as defined in any one of the embodiments 1-13, which method comprises the expression of a vector containing a nucleotide sequence as defined in embodiment 14 in a suitable host cell; and purifying said peptide or dimeric peptide from the expression products of said host cell.

17. A method for reducing the lactose content in a composition containing lactose, such as in a dairy products, comprising the step of contacting said composition with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or enzymatically active fragments thereof, or

any sequence with at least 80 % sequence identity to any one of said sequences or enzymatically active fragments; or a host cell expressing any one of said peptide or dimeric peptide, at a pH ranging from 3-10 and at a temperature ranging from 0°C-140°C.

18. The method according to embodiment 17, wherein said composition is a dairy product
5 selected from the group consisting of lactose-free milk, low-lactose milk, yoghurt, cheese, fermented milk products, dietary supplement and probiotic dietary products.

19. The method according to any one of embodiments 17-18, wherein said host cell is any one selected from a bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*,
10 *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*.

20. The method according to any one of embodiments 17-19, wherein the lactose concentration is reduced to less than about 1%, such as to less than about 0.1% or lower,
15 such as to less than about 0.01%.

21. Use of a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least
20 80 % sequence identity to any one of said sequences; or a host cell expressing any one of said peptide or dimeric peptide for producing a dairy product with a reduced lactose content.

22. The use according to embodiment 21, wherein said dairy product is selected from the group consisting of lactose-free milk, low-lactose milk, yoghurt, cheese, fermented milk products, dietary supplement and probiotic dietary products.

23. The use according to any one of embodiments 21-22, wherein said host cell is any one selected from a bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*,
30 *L. helveticus* or from *Streptococcus thermophilus*.

24. A method for producing a dairy product the method comprising the steps of
a) providing a milk-based substrate comprising lactose;
b) adding an peptide or dimeric peptide exhibiting beta-galactosidase activity, which peptide

has an amino acid sequence represented by SEQ ID NO:1-33; or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences to said milk-based substrate comprising
5 lactose; and
c) treating said milk-based substrate with said peptide or dimeric peptide exhibiting beta-galactosidase activity.

25. The method according to embodiment 24, wherein said peptide or dimeric peptide is derived from any one bacteria of the genus *Bifidobacterium*, such as *Bifidobacterium*
10 *adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium breve*, *Bifidobacterium catenulatum*, *Bifidobacterium longum* or from the genus *Lactobacillus*, such as *L. sakei*, *L. amylovorus*, *L. delbrueckii subsp. bulgaricus*, *L. delbrueckii subsp. lactis*, *L. delbrueckii subsp. Indicus*, *L. crispatus*, *L. reuteri*, *L. helveticus* or from *Streptococcus thermophilus*.

26. The method according to any one of embodiments 24-25, wherein step c) takes place
15 at a pH within a range of 3-10, such as within a range of 3-9, such as within a range of 3-8, such as within a range of 3-7, such as within a range of 3-6, such as within a range of 3-5, such as within a range of 3-4, such as within a range of 4-10, such as within a range of 4-9, such as within a range of 4-8, such as within a range of 4-7, such as within a range of 4-6,
20 such as within a range of 4-5, such as within a range of 5-10, such as within a range of 5-9, such as within a range of 5-8, such as within a range of 5-7, such as within a range of 5-6, such as within a range of 6-10, such as within a range of 6-9, such as within a range of 6-8, such as within a range of 6-7.

27. The method according to any one of embodiments 24-26, wherein step c) or a part of step c) takes place at a temperature of not more than about 25°C, such as not more than
25 about 20 °C, such as not more than about 18 °C, such as not more than about 16 °C, such as not more than about 14 °C, such as not more than about 12 °C, such as not more than about 10 °C, such as not more than about 8 °C, such as not more than about 7 °C, such as not more than about 6 °C, such as not more than about 5 °C, such as not more than about 4 °C, such as not more than about 3 °C, such as not more than about 2 °C.

30 28. The method according to any one of embodiments 24-27, wherein step c) or a part of step c) takes place at a temperature of at least about 25 °C, such as at least about 30 °C, such as at least about 35 °C, such as at least about 40 °C, such as at least about 45 °C, such as at least about 50 °C, such as at least about 55 °C, such as at least about 60 °C, such as at least about 65 °C, such as at least about 70 °C, such as at least about 75 °C, such as at least

about 80 °C, such as at least about 85 °C, such as at least about 90 °C, such as at least about 95 °C, such as at least about 100 °C, such as at least about 110 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 135 °C, such as at least about 140 °C.

5 29. The method according to any one of embodiments 24-28, wherein said dairy product is selected from the group consisting of lactose-free milk, low-lactose milk, yoghurt, cheese, fermented milk products, dietary supplement and probiotic dietary products.

30. The method according to any one of embodiments 24-29, wherein said milk-based substrate is selected from fresh milk or raw milk obtained directly from a step of
10 pasteurization, milk obtained directly after a step of ultra-heat treatment (UHT), or milk obtained directly after a step of fermentation.

31. The method according to any one of embodiments 24-30, wherein the galactose inhibition of said peptide or dimeric peptide is less than 60%, such as less than 55%, such as less than 50%, such as less than about 45%, such as less than about 40%.

15 32. The method according to any one of embodiments 24-31, wherein said dairy product is fermented milk product and said step b) is performed during or prior to fermentation.

33. The method according to embodiment 32, which method does not require the addition of further enzyme after fermentation.

34. The method according to any one of embodiments 24-31, wherein said dairy product
20 is fermented milk product and said step b) is performed immediately following fermentation.

35. The method according to any one of embodiments 24-31, wherein said dairy product is fresh milk and said step b) is performed prior to, in conjunction with, or immediately following a step of pasteurization.

36. The method according to any one of embodiments 24-31, wherein said dairy product
25 is ultra-heat treatment (UHT) milk and said step b) is performed prior to, in conjunction with, or immediately following a step of ultra-heat treatment.

37. The method according to any one of embodiments 24-36, wherein step c) is started at a temperature of between 40°C and 100°C, such as at a temperature of between 50°C and 100°C such as at a temperature of between 60°C and 100°C, such as at a temperature of
30 between 70°C and 100°C, such as at a temperature of between 80°C and 100°C, such as at a temperature of between 40°C and 90°C, such as at a temperature of between 40°C and

80°C, such as at a temperature of between 40°C and 70°C, such as at a temperature of between 40°C and 60°C, such as at a temperature of between 40°C and 50°C.

38. The method according to any one of embodiments 24-37, wherein the peptide or dimeric peptide when hydrolyzing the lactose in the milk-based substrate has a ratio of lactase to transgalactosylase activity of more than 1:1.

39. The method according to any one of embodiments 24-38, wherein less than 80% of the lactose has been hydrolyzed when step c) is completed, and wherein more than 90% of the lactose has been hydrolyzed after one week.

40. A dairy product prepared by a method as defined in any one of embodiments 24-39.

41. A food product, such as a dairy product comprising a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences.

42. A food product, such as a dairy product comprising a host cell expressing a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity, which peptide has an amino acid sequence represented by SEQ ID NO:1-33, or which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or a sequence with at least 80 % sequence identity to any one of said sequences.

43. The food product according to embodiment 42, which is selected from beverages, infant foods, cereals, bread, biscuits, confectionary, cakes, food supplements, dietary supplements, probiotic comestible products, prebiotic comestible products, animal feeds, poultry feeds and medicaments, or a dairy product selected from the group consisting of lactose-free milk, low-lactose milk, dried milk powder, baby milks, yoghurt, ice cream, cheese, fermented milk products, dietary supplement and probiotic dietary products.

Table 1. The gene numbers with corresponding sequence identification number.

Gene number	Sequence Identity number	Species name
G4	SEQ ID No 1	<i>Bifidobacterium adolescentis</i>
G16	SEQ ID No 2 (domain a) SEQ ID No 3 (domain b)	<i>Lactobacillus sakei</i>
G35	SEQ ID No 4	<i>Bifidobacterium adolescentis</i>
G40	SEQ ID No 5 (domain a) SEQ ID No 6 (domain b)	<i>Lactobacillus amylovorus</i>
G44	SEQ ID No 7	<i>Bifidobacterium bifidum</i>
G51	SEQ ID No 8	<i>Bifidobacterium bifidum</i>
G57	SEQ ID No 9	<i>Bifidobacterium breve</i>
G62	SEQ ID No 10	<i>Bifidobacterium catenulatum</i>
G66	SEQ ID No 11	<i>Bifidobacterium catenulatum</i>
G83	SEQ ID No 12	<i>Lactobacillus delbrueckii subsp. bulgaricus</i>
G84	SEQ ID No 13	<i>Lactobacillus delbrueckii subsp. lactis</i>
G95	SEQ ID No 14	<i>Lactobacillus delbrueckii subsp. bulgaricus</i>
G100	SEQ ID No 15	<i>Lactobacillus delbrueckii subsp. bulgaricus</i>
G104	SEQ ID No 16	<i>Lactobacillus delbrueckii subsp. lactis</i>
G108	SEQ ID No 17	<i>Lactobacillus delbrueckii subsp. bulgaricus</i>
G109	SEQ ID No 18	<i>Lactobacillus delbrueckii subsp. bulgaricus</i>
G118	SEQ ID No 19	<i>Lactobacillus delbrueckii subsp. lactis</i>
G145	SEQ ID No 20 (domain a) SEQ ID No 21 (domain b)	<i>Lactobacillus helveticus</i>
G158	SEQ ID No 22	<i>Bifidobacterium longum</i>
G224	SEQ ID No 23 (domain a) SEQ ID No 24 (domain b)	<i>Lactobacillus reuteri</i>
G256	SEQ ID No 25	<i>Lactobacillus delbrueckii subsp. lactis</i>
G282	SEQ ID No 26 (domain a) SEQ ID No 27 (domain b)	<i>Lactobacillus helveticus</i>
G334	SEQ ID No 28 (domain a) SEQ ID No 29 (domain b)	<i>Lactobacillus crispatus</i>
G335	SEQ ID No 30	<i>Streptococcus thermophilus</i>
G336	SEQ ID No 31	<i>Lactobacillus delbrueckii subsp. indicus</i>
G11	SEQ ID No 32	<i>Bifidobacterium adolescentis</i>
G33	SEQ ID No 33	<i>Bifidobacterium adolescentis</i>
G600	SEQ ID No 34	<i>Bifidobacterium bifidum</i>
G500	SEQ ID No 35	<i>Kluyveromyces lactis</i>

EXAMPLES

General material and methods

Molecular cloning and genetic techniques

Techniques for restriction enzyme digestions, ligation, transformation and other standard
5 molecular biology manipulations were based on methods described in the literature (Maniatis
et al. "Molecular cloning: a laboratory manual, 2nd edition" Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY, 1989; Sambrook and Russell "Molecular Cloning: A Laboratory
Manual, 3rd edition" Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2001;
Miller "Experiment in molecular genetics" Cold Spring Harbor Laboratory Press, 1972); or as
10 suggested by the manufacturer. The PCR was carried out in a DNA thermal cycler obtained
from (Bio-Rad, USA). DNA sequencing was performed by LGC, Berlin, Germany. Proteins
were analyzed by polyacrylamide gel electrophoresis (PAGE) under the denaturation
conditions using sodium dodecyl sulphate on gels containing 10% SDS (Mini-PROTEAN® TGX
stain-free™ gel, Biorad, USA). Protein concentrations were determined using BCA method by
15 following the protocol supplied with the kit.

Bacterial strains, plasmid and growth conditions

Escherichia coli strain TOP10 (Invitrogen) was used for the cloning and isolation of plasmids.
The beta-galactosidase deficient *E. coli* strain BW25113 ($\Delta(\text{araD-araB})567$,
 $\Delta\text{lacZ4787}>::\text{rrnB-3}$, λ^- , rph-1 , $\Delta(\text{rhaD-rhaB})568$, hsdR514) (Datsenko KA, Wanner BL;
20 2000, Proc Natl Acad Sci U.S.A. 97: 6640-6645) was used in combination with the pBAD/His
vector (obtained from Invitrogen™ Life Technologies Corporation Europe BV) for recombinant
protein production.

Growth media for protein expression

2xPY medium containing (16 g/L BD BBL™ Phyton TM Peptone, 10 g/L Yeast Extract, 5 g/L
25 NaCl) was used for the recombinant protein production. The growth medium was
supplemented with ampicillin (100 µg/ml) to maintain the plasmid. Protein production was
initiated by adding 0.05% of arabinose in to the culture medium.

Example 1: Construction of the expression vector for the production of lactases

The genomic DNA of the lactic acid bacteria or bifidobacteria was extracted using commercial
30 genomic extraction kit by following the supplied protocol (DNeasy, Qiagen, Germany). The
lactase gene was amplified by PCR using two synthetic primers, using the purified genomic
DNA source as biomass, and the PCR reagents were supplied in the Phusion U Hot start DNA

polymerase (Thermo Scientific, USA) kit. The lactase gene was cloned into the start codon of the expression vector pBAD/His using the USER cloning method (Nour-Eldin HH, Geu-Flores F, Halkier BA, Plant Secondary Metabolism Engineering, Methods in Molecular Biology, 643; 2010), resulting in the expression construct. With the USER cloning method long, complementary overhangs in both PCR product and destination vector were generated. These overhangs can anneal to each other to form a stable hybridization product which was used to transform into *E. coli* without ligation. For the generation of overhangs in the PCR product, a single deoxyuridine residue is included in the upstream region of each primer to amplify target DNA. The lactase gene was amplified using the forward primer (5'-
 10 ATTAACCAUGCGACGCAACTTCGAATGGCC-3') and reverse primer (ATCTTCTC**UTT**ACCGCCTTACCACGAGCACG) containing a uridine at 9th position (as shown in bold), followed by the lactase gene sequence. In parallel, the vector DNA was PCR amplified using the forward (5'-AGAGAAGAU**TTT**CAGCCTGATACAGATTAAATC-3') and reverse primer (5'-ATGGTTAAU**T**CCTCCTGTTAGCCCCAAAAACGG-3') pair containing single deoxyuracil
 15 residue at 9th positions (as highlighted in bold) followed by vector DNA sequence. The PCR products were purified using the commercial PCR purification kit (Qiagen, Denmark). The purified PCR products (lactase gene and the vector DNA) were mixed in equimolar amount and incubated with a commercial USER enzyme mix (New England Biolabs, USA) by following the supplied protocol. These enzymes remove the uracil residue and also the short fragment
 20 upstream of the uridine, thereby creating complementary overhang in the PCR products. These complementary overhangs anneal with each other resulting in the pBAD-lactase expression vector. Aliquots of the ligation mixture were transformed into chemically competent *E. coli* TOP 10 cells. Transformants were selected at 37°C on LB-Amp plates (LB; Luria-Bertani, Amp; 100 µg/ml ampicillin). The following day, colony PCR was carried out
 25 using a small biomass from the overnight grown transformant using the vector primers (primer 1; 5'-CGGCGTCACACTTTGCTATGCC-3' and primer 2; 5'-CCGCGCTACTGCCGCCAGGC-3'). The positive clones from the colony PCR were cultured in 5 mL LB-Amp medium and plasmid DNA was isolated from the cells. The cloned lactase gene was sequenced to verify that no additional mutations had been introduced during the amplification of the gene. The
 30 plasmid DNA was transformed in to the expression host *E. coli* strain BW25113.

Example 2: Expression of lactases in *E. coli* expression host

The lactase enzyme was produced in *E. coli* BW25113 using the pBAD expression system. Freshly transformed *E. coli* BW25113 cells carrying the plasmid DNA were collected from a Lb-Amp plate using a sterile loop and used to inoculate 5 mL of Lb-Amp medium. The

overnight grown culture (200 µL) was used to inoculate 50 mL 2x PY medium (containing 100 µg/mL ampicillin) in a 250 mL flask in a shaker (Innova® 42). The culture was grown at 37°C at 220 rpm until the OD600 reached between 0.6-0.8. The lactase expression was initiated by adding 0.05% arabinose into the culture medium and the cells were cultured for additional 16-20 hours at 18°C at 180 rpm. Cells were harvested by centrifugation (5000 rpm, 10 min at 4°C) and were stored at -20°C until further use.

Example 3: Protein purification using immobilized metal affinity chromatography

Cells from 50 mL culture was thawed on ice and the cells were lysed using 10 mL mixture of lysis buffer (BugBuster® (Novagen) containing 2 mg/mL Lysozyme (Sigma Aldrich), 1 unit Benzonase (Sigma Aldrich), and 1X Complete Protease inhibitor cocktail (EDTA-free, Roche)) by incubating the cells at room temperature for 30 min. After 30 min, the cell debris was removed by centrifugation at 16000 rpm for 20 min at 4°C. The obtained supernatant was filtered through 0.45 µm pore diameter filter. A gravity flow Ni-Sepharose (GE Healthcare) column was prepared with 1 mL slurry by washing out the ethanol and water. The column was then equilibrated with washing buffer (50 mM of NaH₂PO₄, pH 8.0 containing 300 mM of NaCl and 20 mM of Imidazole). The cell-free extract was applied to the column and the non-bound proteins were eluted from the column. The column was washed with 20 mL of washing buffer and the retained proteins were eluted with 3.5 mL of elution buffer (50 mM of NaH₂PO₄, pH 8.0 containing 300 mM of NaCl and 250 mM of imidazole). The collected fractions were analyzed by SDS-PAGE on gels containing 10% acrylamide and those contained the purified lactase enzymes combined together. The buffer was exchanged against the storage buffer (50 mM KH₂PO₄ buffer pH 7.0 containing 10 mM NaCl, 1 mM MgCl₂), using a prepacked PD-10 desalting G-25 gel filtration column (GE Healthcare). The purified enzymes were stored at 4°C until further use.

Example 4: Protein purification using gel filtration chromatography

Cells from 50 mL culture was thawed on ice and the cells were lysed using 10 mL mixture of lysis buffer (BugBuster® (Novagen) containing 2 mg/ml lysozyme, 1 unit Benzonase (Sigma Aldrich), and 1x Complete Protease inhibitor cocktail (EDTA-free, Roche)) by incubating the cells at room temperature (25°C) for 30 min. After 30 min, the cell debris was removed by centrifugation at 16000 rpm for 20 min at 4°C. The obtained supernatant was filtered through 0.45 µm pore diameter filter. The clear cell-free extract was concentrated by filtering through a 30000 Dalton filter (Vivaspin 20, GE Healthcare) by following the supplied protocol. A gravity flow Sephadex G50 superfine (Pharmacia Chemicals, Sweden) column was prepared with 1 g of column material (prepared by boiling in 100 mL water for 1 hour, cooled to room

temperature). A column was prepared by applying 20 mL of the cooled slurry on a 30 mL filtration column. The column was washed with MilliQ water and equilibrated with wash buffer B (50 mM of NaH_2PO_4 buffer, pH 7.0). 500 μL of the concentrated supernatant was applied on the column and allowed the supernatant to enter in the column bed. The wash buffer (50 mM
5 of NaH_2PO_4 buffer, pH 7.0) was applied on top of the column and the eluent fractions were collected individually. The collected fractions were analyzed on SDS-PAGE gel (containing 10% acrylamide). The protein fractions were combined together and buffer was exchanged against the storage buffer (50 mM KH_2PO_4 buffer pH 7.0 containing 10 mM NaCl, 1 mM MgCl_2) with the desalting column as described in earlier section. The purified enzymes were
10 stored at 4°C until further use.

Example 5: Protein concentration measurement using BCA assay

The concentration of purified lactases was determined using Pierce™ BCA protein assay kit (Thermo Fisher Scientific, Germany) by following the protocol supplied with the kit.

Example 6: Activity determination using purified enzymes on lactose as substrate at pH 6.7
15 at 37°C

To measure the beta-galactosidase activity, the purified lactases were diluted to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer B (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μM of MgSO_4). The
20 reaction mixture was prepared by mixing 13 μL of diluted enzyme and 37 μL of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler with the following incubation parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, cooling; 4°C). The reaction mixtures were stored at -20°C until further use. To determine the amount of glucose formed during the reaction, 10 μL of the reaction mixture
25 was transferred to one well of standard microtiter plate (Thermo Fischer Scientific, Denmark) containing 80 μL of buffer C (100 mM of NaH_2PO_4 buffer, pH 7.0, containing glucose oxidase; 0.6 g/L (Sigma Aldrich), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt); ABTS: 1.0 g/L (Sigma Aldrich), horseradish peroxidase; 0.02 g/L (Sigma Adrich)) and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using
30 FLUOStar Omega UV-plate reader (BMG Labtech, Germany). The absorbance values between 0.1 and 1.5 were used for calculations, if the $A_{610\text{ nm}}$ value >1.5, the reaction mixture was diluted up to 10x with buffer A. With each purified enzyme, the reactions were carried out in triplicate and the mean value of the triplicate measurement was used for calculation. The protein purification performed with the *E. coli* cells transformed with the empty pBAD/His was

used for normalization. Using a known concentration of glucose (0–2.5 mM), a standard curve was drawn and the slope of the curve was used to calculate the glucose formed during the reaction. The maximum absorbance value for each lactase was used to determine μmol of glucose formed per min (for example by correlating the absorbance value to the glucose concentration formed using a standard or calibration curve) and is also designated Unit of Lactase Activity 1 (or UAL-1) at pH 6.7 at 37°C. The Specific Activity (designated as SUAL-1) at pH 6.7 at 37°C is defined as μmol of glucose formed per min per mg of enzyme (μmol of glucose/min/mg of enzyme) and is determined by dividing UAL-1 by the protein concentration in mg. The specific activity of SEQ ID NO:34 and SEQ ID NO:35 were determined under essentially the same conditions. The high specific activity at pH 6.7 is highly desired for robustness for the enzyme in fresh and fermented milk applications. The detailed results of the specific activity of enzymes at pH 6.7 at 37°C are described in Figure 22.

Additionally the activity was described as μMof glucose formed per second per μM of enzyme.

The results are shown in Figure 1.

The specific activity of the enzymes was determined at pH 6.7 and at 37°C and used to calculate the approximate time required for hydrolysis of lactose using a fixed enzyme dose based activity units at pH 6.7 at 37°C and 140 mM lactose as substrate (SUAL-1).

The results in terms of time calculated for lactose hydrolysis are shown in **Table 2**:

G No.	SUAL-1	Time required for complete lactose hydrolysis using		
		1 mg enzyme per liter (min)	100 mg enzyme per liter (sec)	47 mg enzyme per liter (sec)
4	118,1	1185	711	1508
11	69,2	2023	1214	2573
16	23,4	5996	3597	7626
33	130,1	1076	646	1369
40	15,8	8874	5324	11287
44	331,5	422	253	537
57	104,6	1339	803	1703
66	187,2	748	449	951
83	272,9	513	308	653
84	161,9	865	519	1100
95	288,1	486	292	618
104	90,5	1548	929	1969
108	277,9	504	302	641
118	113,8	1230	738	1565
158	254,7	550	330	699
282	58,5	2392	1435	3042
335	42,4	3298	1979	4195
500	46,9	2983	1790	3794
600	61,9	2263	1358	2879

TABLE 2. Specific activity of purified enzymes determined at pH 6.7 at 37°C with lactose as substrate, described SUAL-1, discussed in example 6. The calculated time required in seconds for the complete lactose hydrolysis. The measured standard deviation at the given condition was less than 6%. Note *Complete lactose hydrolysis is defined as the time required for the enzyme to hydrolyze 140 mmol of lactose using a fixed enzyme concentration based on specific activity units at pH 6.7 at 37°C with 140 mmol lactose as substrate (SUAL). The theoretical time required to hydrolyze the 140 mmol of lactose is calculated by assuming that reaction rate stay unchanged over the entire reaction period

Example 7: Activity determination using purified enzymes in the presence of galactose at pH 6.7 at 37°C

The purified lactases were diluted to 40x in buffer A (50 mM NaH₂PO₄ buffer pH 6.7 containing 100 µM of MgSO₄). In separate reactions, the diluted enzymes were incubated with buffer D (140 mM of lactose and 140 mM of galactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 µM of MgSO₄). The reaction mixture consists of 13 µL of the diluted enzyme and 37 µL of buffer D in a PCR tube. The reaction mixture was incubated in thermal cycler with the following incubation parameters (reaction time: 10 min at 37°C, enzyme inactivation: 10 min at 95°C, cooling: 4°C). The reaction mixtures were stored at -20°C until further use. To determine the amount of glucose formed during the reaction, 10 µL of the reaction mixture was transferred to one well of standard microtiter plate (Thermo Fischer Scientific, Denmark) containing 80 µL of buffer C (100 mM of NaH₂PO₄ buffer, pH 7.0, containing glucose oxidase; 0.6 g/L (Sigma Aldrich), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt); ABTS: 1.0 g/L (Sigma Aldrich), horseradish peroxidase; 0.02 g/L (Sigma Adrich)) and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader (BMG Labtech, Germany). The absorbance values between 0.1 and 1.5 were used for calculations, if the A₆₁₀ nm value >1.5, the reaction mixture was diluted up to 10x with buffer A. With each purified enzyme, the reactions were carried out in triplicate and the mean value of the triplicate measurement was used for calculation. The protein purification performed with the *E. coli* cells transformed with the empty pBAD/His was used for normalization. Using a known concentration of glucose (0–2.5 mM), a standard curve was drawn and the slope of the curve was used to calculate the absorbance corresponding to 1 µM of glucose formed during the reaction. The maximum absorbance value for each lactase was used to determine µM of glucose formed per sec, described as 1 Unit of Activity with Galactose at pH 6.7 at 37°C (UAG). The specific activity at pH 6.7 at 37°C in presence of galactose is defined as µM of glucose formed per second per µM of enzyme (µM of glucose/sec/µM of enzyme) and determined by dividing UAG by the protein concentration in µM, described as SUAG.

The percentage inhibition of enzymes with galactose is calculated by using the formula

$$\% \text{ inhibition} = 100 \cdot (A - B) / A$$

Where A is specific activity in of enzymes with lactose at pH 6.7 at 37°C (SUAL) as described in the example 6, and B stand for the specific activity of enzymes in presence of galactose at pH 6.7 at 37°C (SUAG) as described in the example 7. The detail results of the % galactose

inhibition are described the Figure 2 and Figure 22. The lower galactose inhibition is highly relevant for the applications where very low lactose concentration is desired. Additionally the activity was described as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 22.

- 5 Note: relatively high standard deviations in galactose inhibition measurement are due to trace amounts of glucose impurities in purchased galactose.

Example 8: Activity determination using purified enzymes on lactose as substrate at pH 6.7 at 4°C

- 10 The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer B (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters
- 15 (reaction time; 60 min at 4°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C freezer until further use. The amount of glucose formed during the reaction was determined by following the protocol described in example 6. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 6.7 at 4°C (UAL-2). The
- 20 specific activity at pH 6.7 at 4°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-2 by the protein concentration in μM , described as SUAL-2. The high specific activity at pH 6.7 at 4°C is highly desired for the lactose hydrolysis for fresh/pasteurized milk applications. The detail results of the specific activity of enzymes at pH 6.7 at 4°C are described in the Figure 3.
- 25 Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in figure 22.

Example 9: Activity determination using purified enzymes on lactose as substrate at pH 6.7 at 43°C

- 30 The purified lactases were diluted to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer B (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing

13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 43°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C freezer until further use. The amount of the glucose formed during the reaction was determined by following the protocol described in example 6. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 6.7 at 43°C (UAL-3). The specific activity at pH 6.7 at 43°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-3 by the protein concentration in μM , described as SUAL-3. The high specific activity at pH 6.7 at 43°C is highly desired for the lactose hydrolysis for the fermented milk applications. The detail results of the specific activity of enzymes at pH 6.7 at 43°C are described in Figure 3b and Figure 4.

Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 22.

Example 10: Activity determination using purified enzymes on lactose as substrate at pH 5.5 at 4°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer E (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 5.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 5.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these two buffers eventually increases the reaction pH from 5.5 to 5.7.

The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 60 min at 4°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C freezer until further use. To determine the amount of glucose formed during the reaction, 10 μL of the reaction mixture was transferred to one well of standard microtiter plate containing 80 μL of buffer C and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader (BMG Labtech, Germany). The absorbance value between 0.1 and 1.5 were used

for calculations, if the A₆₁₀ nm value >1.5, the reaction mixture was diluted up to 5x with buffer A. With each purified enzyme, the reactions were carried out in triplicate and the mean value of the triplicate measurement was used for calculations. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 5.5 at 4°C (UAL-4). The specific activity at pH 5.5 at 4°C is defined as μM of glucose formed per second per μM of enzyme (μM glucose/sec/ μM of enzyme), and is determined by dividing UAL-4 by the protein concentration in μM , described as SUAL-4. The high specific activity at pH 5.5 at 4°C is relevant for the lactose hydrolysis in the fermented milk applications. The detail results of the specific activity of enzymes at pH 5.5 at 4°C are described in the Figure 5.

Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 23.

Example 11: Activity determination using purified enzymes on lactose as substrate at pH 5.5 at 37°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer E (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 5.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 5.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these two buffers eventually increases the reaction pH from 5.5 to 5.7.

The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C until further use. The amount of glucose formed during the reaction was determined by following the protocol as described in the example 10. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 5.5 at 37°C (UAL-5). The specific activity at pH 5.5 at 37°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-5 by the protein concentration in μM , described as SUAL-5. The high specific activity at pH 5.5 at 37°C is relevant for the lactose hydrolysis in the fermented milk applications and sweet whey

lactose hydrolysis. The detail results of the specific activity of enzymes at pH 5.5 at 37°C are described in the Figure 6. Additionally the activity was measured as μ mole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 23.

5 Example 12: Activity determination using purified enzymes on lactose as substrate at pH 5.5 at 43°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer E (140 mM of lactose prepared in 100 mM sodium-citrate
10 buffer of pH 5.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 5.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these two buffers eventually increases the reaction pH from 5.5 to 5.7. The reaction mixture was
15 incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 43°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C until further use. The amount of glucose formed during the reaction was determined by following the protocol described in the example 10. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1
20 Unit of Activity with Lactose at pH 5.5 at 43°C (UAL-6). The specific activity at pH 5.5 at 43°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-6 by the protein concentration in μM , described as SUAL-6. The high specific activity at pH 5.5 at 43°C is relevant for the lactose hydrolysis in the fermented milk applications and sweet whey lactose hydrolysis. The detail results of the
25 specific activity of enzymes at pH 5.5 at 43°C are described in the Figure 7. Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 23.

30 Example 13: Activity determination using purified enzymes on lactose as substrate at pH 4.5 at 4°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer F (140 mM of lactose prepared in 100 mM sodium-citrate

buffer of pH 4.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 4.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these
5 two buffers eventually increases the reaction pH from 4.5 to 4.7.

The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 60 min at 4°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). To determine the amount of glucose formed during the reaction, 10 μL of the reaction mixture was transferred to one well of standard microtiter plate containing 80 μL of buffer C
10 (as described in example 6) and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader. The absorbance value between 0.1 and 1.5 were used for calculations, if the A610 nm value >1.5, the reaction mixture was diluted up to 5x with buffer A. With each purified enzyme, the reactions were carried out in triplicate and the mean value of the triplicate measurement was used for
15 calculation. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 4.5 at 4°C (UAL-7). The specific activity at pH 4.5 at 4°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-7 by the protein concentration in μM , described as SUAL-7. The high specific activity at pH 4.5 at 4°C
20 is relevant for the lactose hydrolysis in the fermented milk applications. The detail results of the specific activity of enzymes at pH 4.5 at 4°C are described in the Figure 8.

Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 24.

25 Example 14: Activity determination using purified enzymes on lactose as substrate at pH 4.5 at 37°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer F (140 mM of lactose prepared in 100 mM sodium-citrate
30 buffer of pH 4.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 4.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these

two buffers eventually increases the reaction pH from 4.5 to 4.7. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C until further use. The amount of glucose formed during the reaction was determined by following the protocol described in the example 13. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 4.5 at 37°C (UAL-8). The specific activity at pH 4.5 at 37°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-8 by the protein concentration in μM , described as SUAL-8. The high specific activity at pH 4.5 at 37°C is relevant for the lactose hydrolysis in the fermented milk applications and acidic whey lactose hydrolysis. The detail results of the specific activity of enzymes at pH 4.5 at 37°C are described in the Figure 9. Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 24.

Example 15: Activity determination using purified enzymes on lactose as substrate at pH 4.5 at 43°C

The purified lactases were diluted up to 40x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with lactose solution prepared in buffer F (140 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 4.5, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The substrate solution was prepared in a buffer of pH 4.5 and enzyme solution had a pH of 6.7. To initiate the reaction, 13 μL of enzyme was added to 37 μL of substrate solution. This mixing of these two buffers eventually increases the reaction pH from 4.5 to 4.7. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 43°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The reaction mixtures were stored at -20°C until further use. The amount of glucose formed during the reaction was determined by following the protocol described in the example 13. The maximum absorbance value for each lactase was used to determine μM of glucose formed per sec, described as 1 Unit of Activity with Lactose at pH 4.5 at 43°C (UAL-9). The specific activity at pH 4.5 at 43°C is defined as μM of glucose formed per second per μM of enzyme (μM of glucose/sec/ μM of enzyme), and is determined by dividing UAL-9 by the protein concentration in μM , described as SUAL-9. The high specific activity at pH 4.5 at 43°C is relevant for the lactose hydrolysis in

the fermented milk applications and acidic whey lactose hydrolysis. The detail results of the specific activity of enzymes at pH 4.5 at 43°C are described in the Figure 10. Additionally the activity was measured as μmole of glucose formed per minute per milligram of enzyme added. The results are shown in Figure 24.

5

Example 16: Activity determination in BLU units

The commercially available NOLA®™ Fit enzyme (Chr-Hansen, Denmark) was diluted in a range from 0.5 BLU/mL to 2.5 BLU/mL in buffer G (50 mM NaH_2PO_4 buffer pH 7.0 containing 100 μM of MgSO_4 , 0.045% Brij, Sigma Aldrich). The diluted enzyme was incubated with
10 lactose solution prepared in buffer H (105 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). The
15 amount of glucose conversion was determined by transferring 10 μL of the reaction mixture in a single well of standard microtiter plate containing 80 μL of buffer C and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader (BMG Labtech, Germany). The measured absorbance values were used to draw a standard curve against BLU/mL. The maximum slope of the curve was used to
20 determine the activity of new enzymes in BLU/mL.

Example 17: Activity determination of new lactases in BLU/mL using lactose as substrate

The purified lactases were diluted up to 50x in buffer A (50 mM NaH_2PO_4 buffer pH 6.7 containing 100 μM of MgSO_4). In a separate reaction, the diluted enzyme was incubated with
25 lactose solution prepared in buffer H (105 mM of lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μM of MgSO_4). The reaction mixture was prepared by mixing 13 μL of diluted purified enzyme and 37 μL of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). After the reaction, 10 μL of the reaction mixture was transferred to one well of standard microtiter
30 plate containing 80 μL of buffer C (as described in example 6) and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader. The absorbance value between 0.1 and 1.5 were used for calculations, if the $A_{610\text{ nm}}$ value >1.5, the reaction mixture was diluted up to 5x with buffer A. The maximum

absorbance values were used to calculate the enzyme activity in BLU/mL, using standard curve described in example 16.

Example 18: Percentage residual lactose measurement in fresh milk at cold temperature

2 mL of commercial pasteurized milk (1.5 % Fat pasteurized milk, Arla Food) was mixed with
5 10-125 μ L of enzyme (equivalent to 10 BLU/mL) as determined in the example 17, in 10 mL
glass tube. The samples were incubated under constant conditions for 24 hours at 4°C. After
the incubation, the reaction was stopped by heat inactivation at 95°C for 7 min, followed by
storage at -20°C until further use. The amount of remaining lactose in the milk was analyzed
using an HPLC assay. Samples for analysis were treated with 1.8 mL protein precipitation
10 solution (0.083 M PCA and 2 mM Na-EDTA) and 2 mL of MQW prior to centrifugation at 2800
rpm for 30 min at 4°C. An aliquot of the supernatant was diluted a total of 200-fold using a
Janus dilution robot (PerkinElmer, Waltham, MA, USA). The diluted samples were analyzed on
a Dionex ICS-5000 system (Thermo Fischer Scientific, Waltham (MA), USA) using 4 x 250
mm CarboPac SA20 analytical column (Thermo Fischer Scientific, Waltham, MA, USA) and a
15 pulsed amperometric detector. The detector was set to a simple three-step potential
waveform, selective for detection of carbohydrates. The eluent was set to 1 mM KOH and was
continuously regenerated through a trap column (CR-TC, Thermo Fischer Scientific, Waltham
(MA), USA). The flow rate of the eluent was 1.2 mL/min and the analysis time was 10 min
per injection. The lactose in each sample was quantified using a three-point external
20 calibration curve prepared by adding known amounts of lactose monohydrate (Sigma-Aldrich,
St. Louis, MO, USA) to MQW. Concentrations were calculated based on the chromatographic
peak heights. The measured percentage residual lactose in fresh milk is shown in Figure 11.

Example 19: Activity determination in UHT milk at room temperature

2 mL of UHT milk (1.5 % Fat UHT milk, Arla Food) was mixed with 2-25 μ L of enzyme
25 (equivalent to 2 BLU/mL) as determined in example 17, in 10 mL glass tube. The samples
were incubated under constant conditions for 24 hours at 25°C. After the incubation, the
reaction was stopped by heat inactivation at 95°C for 7 min, followed by storage at -20°C
until further use. The amount of residual lactose in UHT milk was analyzed using HPLC by
following the protocol as described in example 18. The percentage of residual lactose in fresh
30 milk after hydrolysis is listed in the Figure 12.

Example 20: Enzyme performance at high temperature in buffer

The purified enzyme was diluted to 5 BLU/mL in buffer A (50 mM NaH_2PO_4 buffer pH 6.7
containing 100 μ M of MgSO_4). In a separate reaction, 13 μ L of the diluted enzyme was

incubated in a DNA thermal cycler with lactose solution (105 mM lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μ M of MgSO_4). The reaction mixture was prepared by mixing 13 μ L of enzyme and 37 μ L of lactose solution in a PCR tube. The reaction mixture was incubated in a DNA thermal cycler using the following incubating parameters (reaction time; 10 min at 37°C, enzyme inactivation; 10 min at 95°C, storage; 4°C). After the reaction, 10 μ L of the reaction mixture was transferred to one well of standard microtiter plate containing 80 μ L of buffer C (as described in example 6) and incubated at 30°C for 40 min. After 40 min, the absorbance was determined at 610 nm using FLUOStar Omega UV-plate reader. The absorbance value between 0.1 and 1.5 were used for calculations, if the A610 nm value >1.5, the reaction mixture was diluted up to 5x with buffer A. The measured absorbance was called Abs37°C, and considered as reference value for calculations.

To measure the impact of heat treatment on enzyme activity, in a separate reaction, 13 μ L of the diluted enzyme (5 BLU/mL) was incubated in a DNA thermal cycler using the following incubating parameter (at 72°C for 15 sec or 74°C for 15 sec or 76°C for 6 sec or 78°C for 6 sec or 80°C for 4 sec or 85°C for 5 sec or 90°C for 5 sec or 95°C for 5 sec, followed by storage at 4°C). The activity of the heat treated enzyme was determined by incubation with the lactose solution (105 mM lactose prepared in 100 mM sodium-citrate buffer of pH 6.7, containing 100 μ M of MgSO_4), as described above. The measured absorbance at different temperature (for example at 72°C, 74°C, 76°C, 78°C, 80°C, 85°C, 90°C or 95°C) was called as Abs72°C, Abs74°C, Abs76°C, Abs78°C, Abs80°C, Abs85°C, Abs90°C, Abs95°C.

The percentage residual activity at high temperature was determined using the formula,

$$\% \text{ residual activity} = (\text{Abs72}^\circ\text{C}/\text{Abs37}^\circ\text{C}) * 100$$

The percentages residual activities of different enzymes at different temperature are described in Figure 13.

Example 21: Percentage residual lactose after heat treatment

The effect of heat treatment on the enzyme performance in pasteurized milk was determined by incubating a fixed amount of enzyme in the milk followed by a heat treatment. In separate reactions, 50 μ L of the pasteurized milk was mixed with 10 BLU/mL of purified enzyme (as determined in example 17), in a PCR tube. The milk sample was incubated at 72°C for 15 or 76°C for 10 sec or 85°C for 5 sec and 90°C for 5 sec, followed by incubation at 5°C for 24 h. After 24 h at 5°C, the reaction was stopped by heating the reaction at 95°C for 7 min, followed by storage at -20°C. The residual lactose was measured by using the LactoSens®

assay kit (Chr. Hansen, Denmark), by following the supplied protocol. The measured residual lactose was determined in g/L was determined at different temperature. The detection limit of the LactoSens® kit is between 0.2 g/L to 10 g/L. The results are described in the table 3.

Table 3: The percentage residual lactose in the pasteurized milk treated with a fixed amount of the purified enzyme followed by incubation at different temperature (72°C for 15 sec, 76°C for 10 sec, 85°C for 5 sec and 90°C for 5 sec followed by incubation at 4°C for 24 h), determined using LactoSens® assay kit. The LactoSens® kit detection limits are in range of 0.2 g/L to 10 g/L of lactose. Here ND; not determined.

G-No.	Residual lactose at				
	4 °C (g/ L)	72 °C (g/ L)	76 °C (g/ L)	85 °C (g/ L)	90 °C (g/ L)
G4	<0.2	> 10.0	ND	ND	ND
G11	<0.2	> 10.0	ND	ND	ND
G16	<0.2	> 10.0	ND	ND	ND
G33	<0.2	4.7	ND	ND	ND
G35	<0.2	> 10.0	> 10.0	ND	ND
G40	<0.2	<0.2	<0.2	> 10.0	ND
G44	0.9	> 10.0	ND	ND	ND
G57	<0.2	> 10.0	ND	ND	ND
G62	8.4	> 10.0	> 10.0	> 10.0	ND
G66	0.35	> 10.0	ND	ND	ND
G83	0.3	2.1	6.0	> 10.0	ND
G84	0.25	0.65	0.5	7.6	>10
G95	0.3	6.0	8.6	>10	ND
G100	0.4	2.4	2.6	> 10.0	ND
G104	0.35	0.45	0.5	0.45	>10
G108	0.35	1.3	1.55	ND	ND
G109	0.35	1.45	3.4	> 10.0	ND
G118	0.45	0.95	0.8	> 10.0	>10
G158	<0.2	3.9	> 10.0	ND	ND
G256	0.3	1.0	0.75	3.4	>10
G282	<0.2	<0.2	< 0.2	<0.2	>10
G335	<0.2	0.35	8.0	> 10.0	ND
G600	<0.2	> 10.0	> 10.0	> 10.0	ND
G500	<0.2	> 10.0	ND	ND	ND

Example 22: Percentage residual lactose in pasteurized milk incubated at different temperatures

1 mL of commercial pasteurized milk (1.5% fat milk containing 4.7% lactose, Arla Foods, Denmark) was mixed with 0.047 mg/mL of enzyme, in a 1.5 mL Eppendorf tube. The enzyme
5 was mixed in the milk with gentle vortex or pipetting. 50 µL of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 µL reaction volume. The reaction mixture was incubated in a DNA thermal cycler with the following incubation parameters (reaction temperatures and time; 37°C for 30 min or 55°C for 30 min or 60°C for 30 min, enzyme inactivation temperature and time; 95°C for 10 min,
10 storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature on enzyme performance. After the reaction, the milk samples were either used directly for the residual lactose measurement or stored at -20°C until further use. The residual lactose in the milk was analyzed using LactoSens® assay kit (Chr. Hansen, Denmark) by following the protocol
15 supplied with the kit. The measured percentage residual lactose in the pasteurized milk is shown in Figure 14.

To test the lactose hydrolysis potential of these novel lactases, we incubated 0,047 mg enzyme per millilitre of the pasteurized milk and incubated at 37°C, 55°C and 60°C for 30 min. After 30 min incubation, the enzymes were inactivated by heating at 95°C. The residual
20 lactose was determined using LactoSens® assay kit (Chr. Hansen, Denmark). At their optimal temperature (37°C), both the Ha-Lactase and NOLA® fit showed a high residual lactose (>1% of residual lactose), suggesting that enzymes have lower activity and are not producing lactose free pasteurized milk in the given time frame. Moreover, a similar level of residual lactose was measured at 55°C and 60°C. On the contrary, the G44, G33, G95 and
25 G158 enzymes showed <0.1% residual lactose at 37°C, Figure 15. Because of their high activity at elevated temperatures (55°C or 60°C), the novel enzymes showed <0.01% residual lactose after 30 min incubation. This shows that by using the current enzyme dose it is possible to produce essentially lactose free pasteurized and filtered milk in less than 30 min. Filtered milk is more like raw milk than like pasteurized milk. The lactose hydrolysis at
30 elevated temperature (55°C-60°C) in short time reduces the chance of microbial growth without affecting the milk quality.

Example 23: Percentage residual lactose in pasteurized milk incubated for different time span

1 mL of commercial pasteurized milk (1.5% fat milk containing 4.7% lactose, Arla Foods, Denmark) was mixed with 0.047 mg/mL of enzyme, in a 1.5 mL Eppendorf tube. The enzyme

was mixed in the milk with gentle vortex or pipetting. 50 μ L of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 μ L reaction volume. The reaction mixture was incubated in a DNA thermal cycler with the following incubation parameters (reaction temperatures and time; 55°C for 15 min or 55°C for 30 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature and time. After the reaction, the milk samples either used directly for the residual lactose measurement or stored at -20°C until further use. The residual lactose in the milk was analyzed using LactoSens[®] assay kit (Chr. Hansen, Denmark), as described in the example 22. The measured percentage residual lactose in the pasteurized milk is shown in Figure 16.

Example 24: Percentage residual lactose in pasteurized milk incubated with different enzyme doses

1 mL of commercial pasteurized milk (1.5% fat milk containing 4.7% lactose, Arla Foods, Denmark) was mixed with either different enzyme doses (0.024 mg/mL or 0.047 mg/mL), in 1.5 mL Eppendorf tube. The enzyme was mixed in the milk with gentle vortex or pipetting. 50 μ L of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 μ L reaction volume. The reaction mixture was incubated in a DNA thermal cycler with the following incubation parameters (reaction temperatures and time; 55°C for 30 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). After the reaction, the samples either used directly for the residual lactose measurement or stored at -20°C until further use. The residual lactose in the milk was analyzed by following the same protocol as described in example 22. The measured percentage residual lactose in the pasteurized milk is shown in Figure 17.

Example 25: Percentage residual lactose in pasteurized milk incubated with different enzyme doses and for different reaction time span

1 mL of commercial pasteurized milk (1.5% fat milk containing 4.7% lactose, Arla Foods, Denmark) was mixed with different enzyme dose (0.024 or 0.047 mg/mL), in 1.5 mL Eppendorf tube. The enzyme was mixed in the milk with gentle vortex or pipetting. 50 μ L of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 μ L reaction volume. The reaction mixture was incubated in a DNA thermal cycler with the following incubation parameters (reaction temperatures and

time; 55°C for 15 min or 55°C for 30 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature and time. After the reaction, the samples either used directly used the residual lactose measurement or stored at -20°C until further use. The residual lactose was determined using the protocol described in example 22. The measured percentage residual lactose in the pasteurized milk is shown in Figure 18.

Example 26: Percentage residual lactose in filtered milk

1 mL of commercial micro-filtered semi skimmed milk (1.5% fat milk containing 4.8% lactose, Marguerite, France) was mixed with 0.047 mg/mL of enzyme, in 1.5 mL Eppendorf tube. The enzyme was mixed in the milk with gentle vortex or pipetting. 50 µL of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 µL reaction volume. The reaction mixture was incubated in a DNA thermal cyclor with the following incubation parameters (reaction temperatures and time; 55°C for 30 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature and time. After the reaction, the samples either used directly for the residual lactose measurement or stored at -20°C until further use. The amount of remaining lactose in the milk was analyzed using LactoSens® assay kit (Chr. Hansen, Denmark) by following the protocol supplied with the kit. The measured percentage residual lactose in the filtered milk is shown in Figure 19.

This shows that by using the current enzyme dose it is possible to produce lactose free filtered milk (filtered milk is more like raw milk than pasteurized) in less than 30 min. The lactose hydrolysis at elevated temperature (55°C-60°C) in short time reduces the chance of microbial growth without affecting the milk quality.

Example 27: Percentage residual lactose in filtered milk incubated with different enzyme doses

1 mL of commercial micro-filtered semi skimmed milk (1.5% fat milk containing 4.8% lactose, Marguerite, France) was mixed with different enzyme doses (0.055 mg/mL, 0.55 µM or 0.11 mg/mL, 0.11 µM), in 1.5 mL Eppendorf tube. The enzyme was mixed in the milk with gentle vortex or pipetting. 50 µL of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 µL reaction volume. The reaction mixture was incubated in a DNA thermal cyclor with the following incubation

parameters (reaction temperatures and time; 55°C for 5 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature and time. After the reaction, the samples were either used directly
5 for the residual lactose measurement or stored at -20°C until further use. The residual lactose in the milk was analyzed by following the protocol described in example 22. The measured percentage residual lactose in the filtered milk is shown in Figure 20.

Example 28: Percentage residual lactose in filtered milk incubated for different time span

1 mL of commercial micro-filtered semi skimmed milk (1.5% fat milk containing 4.8%
10 lactose, Marguerite, France) was mixed with 0.11 mg/mL (1 µM) of enzyme, in 1.5 mL Eppendorf tube. The enzyme was mixed in the milk with gentle vortex or pipetting. 50 µL of the milk, containing the enzyme, was transferred to a PCR tube. For each enzyme the reaction was performed in 2x50 µL reaction volume. The reaction mixture was incubated in a
15 DNA thermal cycler with the following incubation parameters (reaction temperatures and time; 55°C for 5 min or 55°C for 6 min or 55°C for 7 min, enzyme inactivation temperature and time; 95°C for 10 min, storage temperature: 4°C). During the enzyme addition, pipetting and mixing the milk samples were kept on ice-water mixture to minimize the effect of temperature and time. After the reaction, the samples either used directly for residual lactose measurement or stored at -20°C until further use. The amount of remaining lactose in the
20 milk was analyzed using LactoSens® assay kit (Chr. Hansen, Denmark) by following the protocol supplied with the kit. The measured percentage residual lactose in the filtered milk is shown in Figure 21.

This shows that by using the current enzyme dose it is possible to produce lactose free pasteurized and filtered milk (filtered milk is more like raw milk than pasteurized) in less than
25 5-30 min. The lactose hydrolysis at elevated temperature (55°C-60°C) in short time reduces the chance of microbial growth without affecting the milk quality.

Claims

1. A peptide exhibiting an increased beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35, wherein:
 - (a) the beta-galactosidase activity is determined by incubating 13 µl of a solution comprising known amount of a purified lactase enzyme and 37 µl of a solution comprising 140 mM lactose at pH 6.7 and 37°C for 10 min, terminating the lactase reaction by heat, determining the amount of glucose formed by incubating the reaction product at 30°C for 40 min with 80 µL of a solution comprising glucose oxidase (0.6 g/L) 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt) (1.0 g/L, ABTS) and horseradish peroxidase (0.02 g/L) and determining the absorbance at 610 nm using a fluophotometer;
 - (b) the increase in beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO: 35 is at least 20%.
2. A peptide according to claim 1, wherein the peptide has an amino acid sequence selected from SEQ ID NO: 22, 33, 14, 13, 19, 7, 9, 11, 26 and 27, 30 and 1 or has an amino acid sequence identity of more than 85% to any of these sequences.
3. A peptide exhibiting beta-galactosidase enzyme activity, which has an amino acid sequence represented by SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or enzymatically active fragments thereof, or an amino acid sequence of any one thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.
4. A dimeric peptide exhibiting beta-galactosidase enzyme activity, which dimeric peptide consist of two peptides having an amino acid sequence represented by SEQ ID NO: 2 and 3, 5 and 6, 20 and 21, 23 and 24, 26 and 27, or 28 and 29; or enzymatically active fragments thereof, or an amino acid sequence of any one thereof having not more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 amino acid substitutions, additions or deletions.
5. A method for reducing the lactose content in a composition containing lactose, such as in a dairy product, including a milk based substrate, comprising the step of contacting said composition with a peptide or dimeric peptide exhibiting beta-galactosidase

enzyme activity according to any one of claims 1 to 4; or a host cell expressing any one of said peptide or dimeric peptide, at a pH ranging from 3-10 and at a temperature ranging from 0°C-140°C.

- 5 6. Use of a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity according to any one of claims 1 to 4 for producing a dairy product with a reduced lactose content.
7. A method for producing a dairy product the method comprising the steps of
- 10 a) providing a milk-based substrate comprising lactose;
- b) adding an peptide or dimeric peptide exhibiting beta-galactosidase activity according to any one of claims 1 to 4 to said milk-based substrate comprising lactose; and
- 15 c) treating said milk-based substrate with said peptide or dimeric peptide exhibiting beta-galactosidase activity.
8. The method according to claim 7, wherein step c) takes place at a pH within a range of 3-10, such as within a range of 3-9, such as within a range of 3-8, such as within a range of 3-7, such as within a range of 3-6, such as within a range of 3-5, such as
- 20 within a range of 3-4, such as within a range of 4-10, such as within a range of 4-9, such as within a range of 4-8, such as within a range of 4-7, such as within a range of 4-6, such as within a range of 4-5, such as within a range of 5-10, such as within a range of 5-9, such as within a range of 5-8, such as within a range of 5-7, such as within a range of 5-6, such as within a range of 6-10, such as within a range of 6-9,
- 25 such as within a range of 6-8, such as within a range of 6-7.
9. The method according to claim 7 or 8, wherein step c) or a part of step c) takes place at a temperature of not more than about 25 °C, such as not more than about 20 °C, such as not more than about 18 °C, such as not more than about 16 °C, such as not
- 30 more than about 14 °C, such as not more than about 12 °C, such as not more than about 10 °C, such as not more than about 8 °C, such as not more than about 7 °C, such as not more than about 6 °C, such as not more than about 5 °C, such as not more than about 4 °C, such as not more than about 3 °C, such as not more than about 2 °C.

10. The method according to any one of claims 7-9, wherein step c) or a part of step c) takes place at a temperature of at least about 25 °C, such as at least about 30 °C, such as at least about 35 °C, such as at least about 40 °C, such as at least about 45 °C, such as at least about 50 °C, such as at least about 55 °C, such as at least about 60 °C, such as at least about 65 °C, such as at least about 70 °C, such as at least about 75 °C, such as at least about 80 °C, such as at least about 85 °C, such as at least about 90 °C, such as at least about 95 °C, such as at least about 100 °C, such as at least about 110 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 120 °C, such as at least about 130 °C, such as at least about 135 °C, such as at least about 140 °C.
11. The method according to any one of claims 5-10, wherein:
- (a) the peptide exhibiting beta-galactosidase activity has an amino acid sequence represented by SEQ ID NO: 22, 33, 14, 7, 26 and 27, 30 and 1 or has an amino acid sequence identity of more than 85% to any of these sequences; and
- (b) peptide exhibits an increased beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO:35, wherein:
- (i) the beta-galactosidase activity is determined by incubating 13 µl of a solution comprising known amount of a purified lactase enzyme and 37 µl of a solution comprising 140 mM lactose at pH 6.7 and 37°C for 10 min, terminating the lactase reaction by heat, determining the amount of glucose formed by incubating the reaction product at 30°C for 40 min with 80 µL of a solution comprising glucose oxidase (0.6 g/L) 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt) (1.0 g/L, ABTS) and horseradish peroxidase (0.02 g/L) and determining the absorbance at 610 nm using a spectrophotometer;
- (ii) the increase in beta-galactosidase enzyme activity in comparison to the peptide of SEQ ID NO: 35 is at least 20%; and
- (c) the step of contacting the composition containing lactose with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity is carried at a temperature between 50°C and 140°C.
12. The method according to any one of claims 5-11, wherein the method reduces the concentration of lactose in the composition containing lactose or in the milk based substrate to less than 0.2%, preferably less than 0.1%.

13. The method according to any one of claims 5-12, wherein the concentration of less than 0.2% lactose in the composition containing lactose or in the milk based substrate is obtained between 3 and 30 minutes, preferably between 4 and 20 minutes, most preferably between 4 and 10 minutes, after adding the peptide exhibiting beta-galactosidase activity.
14. The method according to any one of claims 5-13, wherein the peptide exhibiting beta-galactosidase activity is added to the composition containing lactose so that a mixture comprising a concentration of 0.001 to 0.2 mg/ml lactase is obtained, preferably a concentration of 0.002 to 0.04 mg/ml lactase.
15. The method according to any one of claims 5-14, wherein the step of contacting the composition containing lactose with a peptide or dimeric peptide exhibiting beta-galactosidase enzyme activity is carried out at a temperature between 50°C and 140°C for a time period between 4 and 20 minutes and wherein the milk based product is subsequently cooled and stored until further use at a temperature between 1°C and room temperature, preferably between 1 and 6°C.




Figure 1




Figure 2




Figure 3




Figure 4

5/24




Figure 5

6/24




Figure 6

7/24




Figure 7

8/24




Figure 8

9/24




Figure 9

10/24




Figure 10

11/24




Figure 11

12/24




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21

22/24

G no	pH 6.7 at 4°C	pH 6,7 at 37°C	pH 6,7 at 43°C	% gal inhibition
4	9,4	118,1	84,7	34
11	8,4	69,2	111,3	9
16	1,6	23,4	17,0	45
33	12,5	130,1	173,3	3
35	12,5	121,0	100,9	27
40	1,2	15,8	12,4	53
44	24,2	331,5	295,9	35
51	20,7	250,6	214,3	35
57	7,4	104,6	97,2	47
62	5,2	48,5	37,6	83
66	15,2	187,2	136,8	23
83	26,9	272,9	195,1	37
84	15,9	161,9	118,0	31
95	28,8	288,1	250,7	37
100	27,9	339,9	238,1	39
104	12,9	90,5	112,9	1
108	27,2	277,9	213,1	34
109	25,3	300,1	218,3	30
118	16,9	113,8	122,3	14
145	2,4	24,1	22,6	64
158	34,2	254,7	334,8	27
224	11,2	389,9	131,4	48
256	15,5	111,3	112,8	14
282	8,4	58,5	48,6	62
335	4,4	42,4	30,9	50
500	3,9	46,9	13,1	35
600	7,4	61,9	45,6	44

Figure 22

23/24

G no	pH 5.5 at 4°C	pH 5.5 at 37°C	pH 5.5 at 43°C
4	1,4	44,1	29,6
11	7,6	57,9	75,5
16	0,2	0,7	0,4
33	10,4	88,2	89,9
35	1,7	51,3	40,9
40	3,3	21,8	15,7
44	4,9	111,2	80,7
51	4,0	84,6	58,8
57	0,6	17,8	13,1
62	6,0	60,5	49,7
66	0,8	63,3	42,7
83	6,7	108,4	57,2
84	8,4	99,4	62,4
95	7,0	121,3	64,7
100	5,9	128,2	55,2
104	10,6	60,4	60,5
108	7,0	116,5	69,5
109	5,7	116,5	62,6
118	14,8	76,0	65,0
145	4,9	28,8	15,8
158	18,4	129,4	126,8
224	4,4	21,0	7,4
256	14,0	62,7	57,0
282	6,4	50,8	24,9
335	0,3	9,4	3,1
500	0,1	0,4	0,5
600	4,0	32,7	26,9

Figure 23

24/24

G no	pH 4.5 at 4°C	pH 4.5 at 37°C	pH 4.5 at 43°C
4	1,2	2,9	2,0
11	1,7	18,9	3,3
16	0,1	0	0
33	1,6	24,7	0,7
35	1,6	3,7	2,5
40	3,4	12,9	10,6
44	4,3	12,5	11,8
51	3,9	12,8	11,0
57	0,4	0,1	-0,5
62	4,2	19,9	16,6
66	0,8	1,6	1,2
83	5,6	11,2	12,4
84	7,9	22,7	17,1
95	7,0	12,8	10,4
100	5,6	12,5	11,4
104	4,5	29,7	24,1
108	6,7	14,3	12,8
109	5,5	10,4	19,8
118	5,8	37,5	25,6
145	5,0	8,9	7,2
158	4,2	12,7	25,1
224	4,1	0,0	0,0
256	7,9	23,2	17,2
282	6,3	7,5	7,2
335	0,3	0	0,0
500	0,0	0	0
600	1,6	12,2	5,0

Figure 24

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2018/059283

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07K14/195 C12N9/38
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2007/088324 A1 (LINDSAY CLARE LOUISE [KE]; TZORTZIS GEORGIOS [GB]; GOULAS ATHANASIOS K) 9 August 2007 (2007-08-09) claim 20; sequence 2	1-3,5-15
X	WO 2009/009142 A2 (MONSANTO TECHNOLOGY LLC [US]; ABAD MARK [US]; AHRENS JEFFREY [US]; AUG) 15 January 2009 (2009-01-15) sequences 23716, 12361	1-3
Y	WO 2010/092057 A1 (UINV KOBENHAVNS [DK]; STOUGAARD PETER [DK]; SCHMIDT MARIANE [DK]) 19 August 2010 (2010-08-19) claims 1-24	1-3,5-15
	----- -/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 May 2018

Date of mailing of the international search report

10/07/2018

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Offermann, Stefanie

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2018/059283

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Anonymous: "UNIPROT:A0A0S2MCC8 - beta galactosidase", 17 February 2016 (2016-02-17), XP055457922, Retrieved from the Internet: URL:http://ibis/exam/dbfetch.jsp?id=UNIPROT:A0A0S2MCC8 [retrieved on 2018-03-09]	1-3
Y	the whole document	1-3,5-15
Y	----- EP 2 530 148 A1 (BRAIN BIOTECHNOLOGY RES & INFORMATION NETWORK AG [DE]) 5 December 2012 (2012-12-05) paragraph [0038] -----	1-3,5-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2018/059283

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2018/059283

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-3, 5-15(all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-3, 5-15(all partially)

SEQ ID NO:22 corresponding to G158 and related subject-matter, such as methods/uses of peptides having those sequences

2. claims: 1-3, 5-15(all partially)

SEQ ID NO:33 corresponding to G33; for related subject-matter, see Invention I.

3. claims: 1-3, 5-15(all partially)

SEQ ID NOs:12-19, 25 and 31 (sharing between 89 and 99% identity) corresponding to G83, G84, G95, G100, G104, G108, G109, G118, G256 and G336; for related subject-matter, see Invention I.

4. claims: 1-3, 5-15(all partially)

SEQ ID NOs:7 and 8 (sharing 99% identity) corresponding to G44 and G51; for related subject-matter, see Invention I.

5. claims: 1-3, 5-15(all partially)

SEQ ID NO:9 corresponding to G57; for related subject-matter, see Invention I.

6. claims: 1-3, 5-15(all partially)

SEQ ID NO:11 corresponding to G66; for related subject-matter, see Invention I.

7. claims: 1-15(partially)

SEQ ID NOs:20/21 and 26/27, corresponding to G145 and G282; SEQ ID NOs:20/26 and 21/27 share each 99 % identity, respectively; for related subject-matter, see Invention I.

8. claims: 1-3, 5-15(all partially)

SEQ ID NO:30 corresponding to G335; for related subject-matter, see Invention I.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. claims: 1-3, 5-15(all partially)

SEQ ID N0s:1 and 4 (sharing 99% identity) corresponding to G4 and G35 (see table 1 at p. 32-33 of the application); for related subject-matter, see Invention I.

10. claims: 1, 3-15(all partially)

SEQ ID N0s:2/3 corresponding to G16; for related subject-matter, see Invention I.

11. claims: 1, 3-15(all partially)

SEQ ID N0s:5/6 and 28/29 corresponding to G40 and G334; SEQ ID N0s:5/28 and 6/29 share 99 or 98% identity, respectively; for related subject-matter, see Invention I.

12. claims: 1, 3, 5-15(all partially)

SEQ ID N0:10 corresponding to G62; for related subject-matter, see Invention I.

13. claims: 1, 3-15(all partially)

SEQ ID N0s:23/24 corresponding to G224; for related subject-matter, see Invention I.

14. claims: 1, 3, 5-15(all partially)

SEQ ID N0:32 corresponding to G11; for related subject-matter, see Invention I.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2018/059283

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2007088324 A1	09-08-2007	AT 507287 T	15-05-2011
		AU 2007211356 A1	09-08-2007
		BR PI0707327 A2	03-05-2011
		CA 2637219 A1	09-08-2007
		CN 101379186 A	04-03-2009
		CY 1111684 T1	07-10-2015
		DK 1979473 T3	23-05-2011
		EP 1979473 A1	15-10-2008
		ES 2364370 T3	01-09-2011
		GB 2447006 A	27-08-2008
		HK 1121779 A1	02-09-2011
		IL 192892 A	31-07-2014
		JP 4960974 B2	27-06-2012
		JP 2009525037 A	09-07-2009
		KR 20080098598 A	11-11-2008
		MY 148861 A	14-06-2013
		NO 341882 B1	12-02-2018
		NZ 569198 A	27-08-2010
		PT 1979473 E	12-05-2011
		UA 95944 C2	26-09-2011
		US 2009110770 A1	30-04-2009
		WO 2007088324 A1	09-08-2007
		ZA 200806175 B	29-07-2009
-----	-----	-----	-----
WO 2009009142 A2	15-01-2009	EP 2175714 A2	21-04-2010
		EP 2380988 A2	26-10-2011
		EP 2573178 A2	27-03-2013
		US 2011265221 A1	27-10-2011
		US 2013283461 A1	24-10-2013
		US 2016230183 A1	11-08-2016
		WO 2009009142 A2	15-01-2009
-----	-----	-----	-----
WO 2010092057 A1	19-08-2010	CA 2751957 A1	19-08-2010
		CN 102361974 A	22-02-2012
		DK 2396403 T3	11-01-2016
		EP 2396403 A1	21-12-2011
		US 2012058223 A1	08-03-2012
		WO 2010092057 A1	19-08-2010
-----	-----	-----	-----
EP 2530148 A1	05-12-2012	NONE	
-----	-----	-----	-----